US20190247476A1 - Non-protein clostridial toxin compositions - Google Patents

Non-protein clostridial toxin compositions Download PDF

Info

Publication number
US20190247476A1
US20190247476A1 US16/332,923 US201716332923A US2019247476A1 US 20190247476 A1 US20190247476 A1 US 20190247476A1 US 201716332923 A US201716332923 A US 201716332923A US 2019247476 A1 US2019247476 A1 US 2019247476A1
Authority
US
United States
Prior art keywords
poloxamer
composition
methionine
trehalose
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/332,923
Other languages
English (en)
Inventor
Maurice Abiad
Bhas Dani
Evgenyi Shalaev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59974865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20190247476(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US16/332,923 priority Critical patent/US20190247476A1/en
Publication of US20190247476A1 publication Critical patent/US20190247476A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to solid and liquid pharmaceutical compositions comprising a clostridial toxin active ingredient and one or more non-protein excipient.
  • a pharmaceutical composition is a formulation which contains at least one active ingredient (such as a Clostridial toxin) as well as, for example, one or more excipients, buffers, carriers, stabilizers, preservatives and/or bulking agents, and is suitable for administration to a patient to achieve a desired diagnostic result or therapeutic effect.
  • active ingredient such as a Clostridial toxin
  • excipients such as a Clostridial toxin
  • a pharmaceutical composition can be formulated as a lyophilized (i.e. freeze dried) or vacuum dried powder which can be reconstituted with a suitable fluid, such as saline or water, prior to administration to a patient.
  • the pharmaceutical composition can be formulated as an aqueous solution or suspension.
  • a pharmaceutical composition can contain a proteinaceous active ingredient.
  • a protein active ingredient can be very difficult to stabilize (i.e. maintained in a state where loss of biological activity is minimized), thereby resulting in a loss of protein and/or loss of protein activity during the formulation, reconstitution (if required) and storage of the pharmaceutical composition prior to use.
  • Stability problems can arise due to surface adsorption of a protein active ingredient, physical instability, such as, e.g., denaturation or aggregation, or chemical instability, such as, e.g., cross-linking, deamidation, isomerization, oxidation, formation of acidic or basic species, Maillard reaction, and fragmentation.
  • physical instability such as, e.g., denaturation or aggregation
  • chemical instability such as, e.g., cross-linking, deamidation, isomerization, oxidation, formation of acidic or basic species, Maillard reaction, and fragmentation.
  • albumin and gelatin have been used to stabilize a protein active ingredient present in a pharmaceutical composition.
  • protein excipients such as albumin or gelatin
  • albumin and gelatin are expensive and increasingly difficult to obtain.
  • blood products or animal derived products such as albumin and gelatin, when administered to a patient can subject the patient to a potential risk of receiving blood borne pathogens or infectious agents.
  • an animal-derived protein excipient in a pharmaceutical composition can result in inadvertent incorporation of infectious elements into the pharmaceutical composition.
  • human serum albumin may transmit prions into a pharmaceutical composition.
  • suitable non-protein excipients such as, e.g., stabilizers, cryo-protectants and lyo-protectants, which can be used to stabilize the protein active ingredient present in a pharmaceutical composition.
  • Clostridial toxins further constrain and hinder the selection of suitable non-protein excipients for a pharmaceutical composition comprising a Clostridial toxin active ingredient.
  • Clostridial toxins are large proteins having an average molecular weight of approximately 150 kDa, and are further complexed with non-toxin associated proteins that increase the size to approximately 300-900-kDa.
  • the size of a Clostridial toxin complex makes it much more fragile and labile than smaller, less complex proteins, thereby compounding the formulation and handling difficulties if Clostridial toxin stability is to be maintained.
  • non-protein excipients such as, e.g., stabilizers, cryo-protectants and lyo-protectants must be able to interact with the Clostridial toxin active ingredient in a manner which does not denature, fragment or otherwise inactivate the toxin or cause disassociation of the non-toxin associated proteins present in the toxin complex.
  • Clostridial toxin active ingredient Another problem associated with a Clostridial toxin active ingredient, is the exceptional safety, precision, and accuracy that is necessary for at all steps of the formulation process. Thus, a non-protein excipient should not itself be toxic or difficult to handle so as to not exacerbate the already extremely stringent requirements.
  • Clostridial toxin active ingredient is the enormous low amounts of Clostridial toxin that is used in a pharmaceutical composition.
  • the biological activities of the Clostridial toxins are dependant, at least in part, upon their three dimensional conformation.
  • a Clostridial toxin is detoxified by heat, various chemicals, surface stretching, and surface drying.
  • dilution of a Clostridial toxin complex obtained by the known culturing, fermentation and purification methods results in rapid inactivation of the toxin.
  • Clostridial toxin active ingredient that is used in a pharmaceutical composition, makes this active ingredient very susceptible to adsorption to, e.g., the surfaces of laboratory glassware, vessels, to the vial in which the pharmaceutical composition is reconstituted and to the inside surface of a syringe used to inject the pharmaceutical composition.
  • Such adsorption of a Clostridial toxin active ingredient to surfaces can lead to a loss of active ingredient and to denaturation of the remaining Clostridial toxin active ingredient, both of which reduce the total activity of the active ingredient present in the pharmaceutical composition.
  • non-protein excipients such as, e.g., stabilizers, cryo-protectants and lyo-protectants must be able to act as surface blockers to prevent the adsorption of a Clostridial toxin active ingredient to a surface.
  • the pH-sensitivity associates with complex formation is known to be soluble in dilute aqueous solutions at pH 3.5-6.8.
  • the non-toxic associated proteins dissociate from the 150-kDa neurotoxin, resulting in a loss of toxicity, particularly as the pH rises above pH 8.0.
  • Edward J. Schantz et al., pp. 44-45 Preparation and characterization of botulinum toxin type A for human treatment , in Jankovic, J., et al., Therapy with Botulinum Toxin (Marcel Dekker, Inc., 1994).
  • non-protein excipients useful to formulate a pharmaceutical composition comprising a Clostridial toxin active ingredient must be able to operate within the confines of a pH level necessary to maintain the activity a Clostridial toxin active ingredient.
  • Clostridial toxin pharmaceutical composition wherein a Clostridial toxin active ingredient (such as a botulinum toxin) is stabilized by a non-protein excipient.
  • the present invention relates to solid and liquid Clostridial toxin pharmaceutical compositions with one or more non-protein excipients which functions to stabilize the Clostridial toxin active ingredient present in the solid or liquid pharmaceutical composition.
  • a pharmaceutical composition comprising a Clostridial toxin active ingredient, a tonicity agent, a surfactant and an antioxidant.
  • the pharmaceutical compositions comprises a botulinum toxin.
  • the pharmaceutical composition comprises trehalose.
  • the pharmaceutical composition comprises sodium chloride.
  • the composition comprises a poloxamer and/or a polysorbate.
  • the composition comprises poloxamer 188 and/or polysorbate 20.
  • the antioxidant is selected from the group consisting of L-methionine, N-Acetyl-cystein (NAC), butylated hydroxytoluene (BHT), ethylene diamine tetraacetic acid sodium salt (EDTA), an EDTA analog, ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), an EGTA analog, diethylenetriaminepentaacetic acid (DTPA), a DTPA analog, ascorbic acid, and combinations thereof.
  • the antioxidant is methionine.
  • the antioxidant is NAC.
  • the antioxidant is NAC and EDTA.
  • the composition further comprises a buffering agent.
  • the buffering agent includes histidine buffer.
  • the composition has a pH of from 5 to 7.
  • the composition is a liquid formulation. In some embodiments, the composition is a solid formulation.
  • the present disclosure provides a liquid pharmaceutical composition
  • a liquid pharmaceutical composition comprising a Clostridial toxin active ingredient, trehalose, poloxamer 188 or polysorbate 20, and L-methionine or N-acetyl-cysteine (NAC).
  • the liquid pharmaceutical composition comprises a botulinum toxin.
  • the liquid pharmaceutical composition further comprises EDTA or an EDTA analog.
  • the liquid pharmaceutical composition comprises a histidine buffer.
  • the pH of the liquid pharmaceutical composition ranges from 5 to 7.
  • the relative weight amount of L-methionine ranges from about 0.1% to about 0.3%.
  • the relative weight amount of NAC ranges from about 0.1% to about 0.5%.
  • the relative weight amount of EDTA ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of trehalose ranges from about 1.0 to about 10%. In some embodiments, the relative weight amount of poloxamer 188 ranges from about 2% to about 5%. In some embodiments, the relative weight amount of polysorbate 20 ranges from about 0.02% to about 0.06%.
  • the present disclosure provides a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising a botulinum toxin, trehalose, poloxamer 188 or polysorbate 20, NAC, and EDTA or an EDTA analog.
  • the solid pharmaceutical composition comprises a botulinum toxin, trehalose, poloxamer 188, and NAC.
  • the solid pharmaceutical composition comprises a botulinum toxin, trehalose, poloxamer 188 and L-methionine.
  • the solid pharmaceutical composition further comprises histidine buffer.
  • the relative weight amount of L-methionine ranges from about 0.1% to about 0.3%.
  • the relative weight amount of NAC ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of EDTA ranges from about 0.01% to about 0.05%. In some embodiments, the relative weight amount of trehalose ranges from about 1.0 to about 10%. In some embodiments, the relative weight amount of poloxamer 188 ranges from about 0.5% to about 5%. In some embodiments, the relative weight amount of polysorbate 20 ranges from about 0.02% to about 0.06%.
  • compositions of the present invention provide stable liquid or solid pharmaceutical composition comprising a clostridical toxin active ingredient, a disaccharide, a surfactant and an antioxidant.
  • the disaccharide is optional.
  • Certain embodiments also provide methods for the treatment of various diseases, disorders, and conditions, including, for example, depression (e.g. major depressive disorder), headache (e.g. migraine, tension headache, and the like), pain, atrial fibrillation, hyperhidrosis, muscle spasticity, cervical dystonia, blepherospasm, overactive bladder (e.g. neurogenic detrusor overactivity, and idiopathic overactive bladder), bladder pain (e.g. interstitial cystitis, bladder pain syndrome), skin conditions (e.g. wrinkles, fine wrinkles, excess sebum production, acne, rosacea), irregularities, and the like using the compositions provided according to aspect of the present invention.
  • Embodiments can include various administration techniques, including, for example, injection, such as intramusclular, intracutaneous, subcutaneous, or the like, instillation, intravenous, transdermal, and topical.
  • an element means one element or more than one element.
  • “About” or “approximately” as used herein means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, (i.e., the limitations of the measurement system). For example, “about” can mean within 1 or more than 1 standard deviations, per practice in the art. Where particular values are described in the application and claims, unless otherwise stated, the term “about” means within an acceptable error range for the particular value.
  • administering means the step of giving (i.e. administering) a pharmaceutical composition to a subject, or alternatively a subject receiving a pharmaceutical composition.
  • the pharmaceutical compositions disclosed herein can be locally administered by various methods. For example, intramuscular, intradermal, subcutaneous administration, intrathecal administration, intraperitoneal administration, topical (transdermal), instillation, and implantation (for example, of a slow-release device such as polymeric implant or miniosmotic pump) can all be appropriate routes of administration.
  • “Alleviating” means a reduction in the occurrence of a pain, of a headache, or of any symptom or cause of a condition or disorder. Thus, alleviating includes some reduction, significant reduction, near total reduction, and total reduction.
  • an animal protein free pharmaceutical composition can include a botulinum neurotoxin.
  • an “animal protein free” pharmaceutical composition means a pharmaceutical composition which is either substantially free or essentially free or entirely free of a serum derived albumin, gelatin and other animal derived proteins, such as immunoglobulins.
  • An example of an animal protein free pharmaceutical composition is a pharmaceutical composition which comprises or which consists of a botulinum toxin (as the active ingredient) and a suitable polysaccharide as a stabilizer or excipient.
  • Antioxidant refers to any compound which protects an active ingredient from reaction with oxygen.
  • Antioxidants can be broadly divided into three categories: (i) sacrificial antioxidants, which react with oxygen more readily than a particular active ingredient and therefore can scavenge oxygen, e.g., ascorbic acid and sulfites; (ii) chain terminators, which are molecules that form stable radicals due to weak bonds to hydrogen atoms that are attacked in a propagation of radical chains by consumption of oxygen, e.g., methionine, NAC, glutathionine, lipoic acid, butylated hydroxytoluene (BHT), and cysteine, (iii) chelating agents, which reduce catalytic activity of transition metals by forming complexes with the metals, e.g., EDTA, EGTA and DTPA and analogs thereof.
  • sacrificial antioxidants which react with oxygen more readily than a particular active ingredient and therefore can scavenge oxygen, e
  • Bio activity describes the beneficial or adverse effects of a drug on living matter. When a drug is a complex chemical mixture, this activity is exerted by the substance's active ingredient but can be modified by the other constituents. Biological activity can be assessed as potency or as toxicity by an in vivo LD 50 or ED 50 assay, or through an in vitro assay such as, for example, cell-based potency assays (CBPAs) as described in U.S. 20100203559 and U.S. 20100233802. The activities of the compositions of the invention may be measured using any sutiable assay and are not limited to activities measured by CBPA. The potency described in the examples also encompasses potency when measured using LD50.
  • CBPAs cell-based potency assays
  • Botulinum toxin means a neurotoxin produced by Clostridium botulinum , as well as a botulinum toxin (or the light chain or the heavy chain thereof) made recombinantly by a non-Clostridial species.
  • botulinum toxin encompasses the botulinum toxin serotypes A, B, C, D, E, F and G, and their subtypes and any other types of subtypes thereof, or any re-engineered proteins, analogs, derivatives, homologs, parts, sub-parts, variants, or versions, in each case, of any of the foregoing.
  • botulinum toxin also encompasses a “modified botulinum toxin”. Further “botulinum toxin” as used herein also encompasses a botulinum toxin complex, (for example, the 300, 600 and 900 kDa complexes), as well as the neurotoxic component of the botulinum toxin (150 kDa) that is unassociated with the complex proteins.
  • Clostridial toxin refers to any toxin produced by a Clostridial toxin strain that can execute the overall cellular mechanism whereby a Clostridial toxin intoxicates a cell and encompasses the binding of a Clostridial toxin to a low or high affinity Clostridial toxin receptor, the internalization of the toxin/receptor complex, the translocation of the Clostridial toxin light chain into the cytoplasm and the enzymatic modification of a Clostridial toxin substrate.
  • Clostridial toxins include a Botulinum toxin like BoNT/A, a BoNT/B, a BoNT/C 1 , a BoNT/D, a BoNT/E, a BoNT/F, a BoNT/G, a Tetanus toxin (TeNT), a Baratii toxin (BaNT), and a Butyricum toxin (BuNT).
  • Clostridial toxin includes, without limitation, naturally occurring Clostridial toxin variants, such as, e.g., Clostridial toxin isoforms and Clostridial toxin subtypes; non-naturally occurring Clostridial toxin variants, such as, e.g., conservative Clostridial toxin variants, non-conservative Clostridial toxin variants, Clostridial toxin chimeric variants and active Clostridial toxin fragments thereof, or any combination thereof.
  • naturally occurring Clostridial toxin variants such as, e.g., Clostridial toxin isoforms and Clostridial toxin subtypes
  • non-naturally occurring Clostridial toxin variants such as, e.g., conservative Clostridial toxin variants, non-conservative Clostridial toxin variants, Clostridial toxin chimeric variants and active Clostridial toxin fragments
  • a Clostridial toxin disclosed herein also includes a Clostridial toxin complex.
  • Clostridial toxin complex refers to a complex comprising a Clostridial toxin and non-toxin associated proteins (NAPs), such as, e.g., a Botulinum toxin complex, a Tetanus toxin complex, a Baratii toxin complex, and a Butyricum toxin complex.
  • NAPs non-toxin associated proteins
  • Non-limiting examples of Clostridial toxin complexes include those produced by a Clostridium botulinum , such as, e.g., a 900-kDa BoNT/A complex, a 500-kDa BoNT/A complex, a 300-kDa BoNT/A complex, a 500-kDa BoNT/B complex, a 500-kDa BoNT/C 1 complex, a 500-kDa BoNT/D complex, a 300-kDa BoNT/D complex, a 300-kDa BoNT/E complex, and a 300-kDa BoNT/F complex.
  • a Clostridium botulinum such as, e.g., a 900-kDa BoNT/A complex, a 500-kDa BoNT/A complex, a 300-kDa BoNT/A complex, a 500-kDa BoNT/B complex, a 500-kDa BoNT/C 1 complex, a 500-kD
  • Clostridial toxin active ingredient refers to a molecule which contains any part of a clostridial toxin that exerts an effect upon or after administration to a subject or patient.
  • the term “clostridial toxin active ingredient” encompasses a Clostridial toxin complex comprising the approximately 150-kDa Clostridial toxin and other proteins collectively called non-toxin associated proteins (NAPs), the approximately 150-kDa Clostridial toxin alone, or a modified Clostridial toxin, such as, e.g., a re-targeted Clostridial toxins.
  • NAPs non-toxin associated proteins
  • “Deformity” means a cosmetic, physical or functional irregularity, defect, abnormality, imperfection, malformation, depression, or distortion.
  • Effective amount as applied to the biologically active ingredient means that amount of the ingredient which is generally sufficient to effect a desired change in the subject. For example, where the desired effect is a reduction in an autoimmune disorder symptom, an effective amount of the ingredient is that amount which causes at least a substantial reduction of the autoimmune disorder symptom, and without resulting in significant toxicity.
  • Effective amount when used in reference to the amount of an excipient or specific combination of excipients added to a Clostridial toxin composition, refers to the amount of each excipient that is necessary to achieve the desired initial recovered potency of a Clostridial toxin active ingredient.
  • an effective amount of an excipient or combination of excipients results in an initial recovered potency of, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
  • a therapeutically effective concentration of a Clostridial toxin active ingredient reduces a symptom associated with the aliment being treated by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
  • Heavy chain means the heavy chain of a botulinum neurotoxin. It has a molecular weight of about 100 kDa and can be referred to as the H chain, or as H.
  • He means a fragment (about 50 kDa) derived from the H chain of a botulinum neurotoxin which is approximately equivalent to the carboxyl end segment of the H chain, or the portion corresponding to that fragment in the intact H chain. It is believed to be immunogenic and to contain the portion of the natural or wild type botulinum neurotoxin involved in high affinity, presynaptic binding to motor neurons.
  • H N means a fragment (about 50 kDa) derived from the H chain of a botulinum neurotoxin which is approximately equivalent to the amino end segment of the H chain, or the portion corresponding to that fragment in the intact in the H chain. It is believed to contain the portion of the natural or wild type botulinum neurotoxin involved in the translocation of the L chain across an intracellular endosomal membrane.
  • Light chain means the light chain of a clostridial neurotoxin. It has a molecular weight of about 50 kDa, and can be referred to as the L chain, L, or as the proteolytic domain (amino acid sequence) of a botulinum neurotoxin.
  • LH N or L-H N means a fragment derived from a clostridial neurotoxin that contains the L chain, or a functional fragment thereof coupled to the H N domain It can be obtained from the intact clostridial neurotoxin by proteolysis, so as to remove or to modify the He domain.
  • Implant means a controlled release (e.g., pulsatile or continuous) composition or drug delivery system.
  • the implant can be, for example, injected, inserted or implanted into a human body.
  • Liquid composition “Liquid composition”, “liquid pharmaceutical composition”, or “liquid formulation” refers to a pharmaceutically active preparation of drug or biologically active ingredient which is capable of being stored in a liquid pharmaceutical excipient, such as a buffering agent, for an extended period of time, such that it can be ready-to-use as needed by a clinician.
  • the liquid pharmaceutical composition is manufactured without a lyophilization process.
  • “Local administration” means direct administration of a pharmaceutical at or to the vicinity of a site on or within an animal body, at which site a biological effect of the pharmaceutical is desired, such as via, for example, intramuscular or intra- or subdermal injection or topical administration.
  • Topical administration is a type of local administration in which a pharmaceutical agent is applied to a patient's skin.
  • Lyoprotector or “lyoprotectant” means a substance that is included in a lyophilized formulation to protect a Clostridial toxin active ingredient during the freeze-drying process.
  • Lyoprotectors include for example polyhydroxy compounds such as sugars (mono-, di-, and polysaccharides), polyalcohols, and their derivatives.
  • Exemplary lyoprotectors which can be used with the lyophilized formulations disclosed herein include sucrose, trehalose, mannitol, sorbitol, glucose, raffinose, maltose, glycerol, lactose, fructose, galactose, and combinations thereof.
  • “Lyophilized composition”, “lyophilized pharmaceutical composition”, “lyophilized formulation”, or “solid composition” refers to a formulation containing a Clostridial toxin active ingredient which has been subjected to a lyophilization, freeze-drying or vacuum-drying process; and can be reconstituted with a reconstitution vehicle, such as for example saline or water, prior to administration to a patient.
  • the lyophilized composition can be a freeze-dried composition or a vacuum-dried composition.
  • Modified botulinum toxin means a botulinum toxin that has had at least one of its amino acids deleted, modified, or replaced, as compared to a native botulinum toxin. Additionally, the modified botulinum toxin can be a recombinantly produced neurotoxin, or a derivative or fragment of a recombinantly made neurotoxin. A modified botulinum toxin retains at least one biological activity of the native botulinum toxin, such as, the ability to bind to a botulinum toxin receptor, or the ability to inhibit neurotransmitter release from a neuron.
  • modified botulinum toxin is a botulinum toxin that has a light chain from one botulinum toxin serotype (such as serotype A), and a heavy chain from a different botulinum toxin serotype (such as serotype B).
  • a modified botulinum toxin is a botulinum toxin coupled to a neurotransmitter, such as substance P.
  • “Mutation” means a structural modification of a naturally occurring protein or nucleic acid sequence.
  • a mutation can be a deletion, addition or substitution of one or more nucleotides in the DNA sequence.
  • the mutation can be a deletion, addition or substitution of one or more amino acids in a protein sequence.
  • a specific amino acid comprising a protein sequence can be substituted for another amino acid, for example, an amino acid selected from a group which includes the amino acids alanine, aspargine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine or any other natural or non-naturally occurring amino acid or chemically modified amino acids.
  • Mutations to a protein sequence can be the result of mutations to DNA sequences that when transcribed, and the resulting mRNA translated, produce the mutated protein sequence. Mutations to a protein sequence can also be created by fusing a peptide sequence containing the desired mutation to a desired protein sequence.
  • “Patient” means a human or non-human subject receiving medical or veterinary care. Accordingly, the compositions as disclosed herein can be used in treating any animal, such as, for example, mammals, or the like.
  • “Peripherally administering” or “peripheral administration” means subdermal, intradermal, transdermal, or subcutaneous administration, but excludes intramuscular administration. “Peripheral” means in a subdermal location, and excludes visceral sites.
  • “Pharmaceutical composition” means a composition comprising an active pharmaceutical ingredient, such as, for example, a clostridial toxin active ingredient such as a botulinum toxin, and at least one additional ingredient, such as, for example, a stabilizer or excipient or the like.
  • a pharmaceutical composition is therefore a formulation which is suitable for diagnostic or therapeutic administration to a subject, such as a human patient.
  • the pharmaceutical composition can be, for example, in a lyophilized or vacuum dried condition, a solution formed after reconstitution of the lyophilized or vacuum dried pharmaceutical composition, or as a solution or solid which does not require reconstitution.
  • “Pharmacologically acceptable excipient” is synonymous with “pharmacological excipient” or “excipient” and refers to any excipient that has substantially no long term or permanent detrimental effect when administered to mammal and encompasses compounds such as, e.g., stabilizing agent, a bulking agent, a cryo-protectant, a lyo-protectant, an additive, a vehicle, a carrier, a diluent, or an auxiliary.
  • An excipient generally is mixed with an active ingredient, or permitted to dilute or enclose the active ingredient and can be a solid, semi-solid, or liquid agent.
  • a pharmaceutical composition comprising a Clostridial toxin active ingredient can include one or more pharmaceutically acceptable excipients that facilitate processing of an active ingredient into pharmaceutically acceptable compositions.
  • any pharmacologically acceptable excipient is not incompatible with the Clostridial toxin active ingredient, its use in pharmaceutically acceptable compositions is contemplated.
  • Non-limiting examples of pharmacologically acceptable excipients can be found in, e.g., Pharmaceutical Dosage Forms and Drug Delivery Systems (Howard C. Ansel et al., eds., Lippincott Williams & Wilkins Publishers, 7 th ed. 1999); Remington: The Science and Practice of Pharmacy (Alfonso R.
  • the constituent ingredients of a pharmaceutical composition can be included in a single composition (that is, all the constituent ingredients, except for any required reconstitution fluid, are present at the time of initial compounding of the pharmaceutical composition) or as a two-component system, for example a vacuum-dried composition reconstituted with a reconstitution vehicle which can, for example, contain an ingredient not present in the initial compounding of the pharmaceutical composition.
  • a two-component system can provide several benefits, including that of allowing incorporation of ingredients which are not sufficiently compatible for long-term shelf storage with the first component of the two component system.
  • the reconstitution vehicle may include a preservative which provides sufficient protection against microbial growth for the use period, for example one-week of refrigerated storage, but is not present during the two-year freezer storage period during which time it might degrade the toxin.
  • Other ingredients which may not be compatible with a botulinum toxin or other ingredients for long periods of time, can be incorporated in this manner; that is, added in a second vehicle (e.g. in the reconstitution vehicle) at the approximate time of use.
  • a pharmaceutical composition can also include preservative agents such as benzyl alcohol, benzoic acid, phenol, parabens and sorbic acid.
  • compositions can include, for example, excipients, such as surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; antioxidants; stabilizing agents; and pharmaceutically acceptable polymeric or hydrophobic materials and other ingredients known in the art and described, for example in Genaro, ed., 1985, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., which is incorporated herein by reference.
  • excipients such as surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; preservatives; physiologically degradable compositions such as gelatin;
  • Polysaccharide means a polymer of more than two saccharide molecule monomers.
  • the monomers can be identical or different.
  • Stabilizing agent means a substance that acts to stabilize a Clostridial toxin active ingredient such that the potency of the pharmaceutical composition is increased relative to an unstabilized composition.
  • “Stabilizers” can include excipients, and can include protein and non-protein molecules.
  • “Surfactant” refers to a natural or synthetic amphiphilic compound.
  • a surfactant can be non-ionic, zwitterionic, or ionic.
  • Non-limiting examples of surfactants include a poloxamer, a polysorbate, and combinations thereof.
  • “Therapeutic formulation” means a formulation can be used to treat and thereby alleviate a disorder or a disease, such as, for example, a disorder or a disease characterized by hyperactivity (i.e. spasticity) of a peripheral muscle.
  • TEM is synonymous with “Targeted Exocytosis Modulator” or “retargeted endopeptidase.”
  • a TEM comprises an enzymatic domain from a Clostridial toxin light chain, a translocation domain from a Clostridial toxin heavy chain, and a targeting domain.
  • the targeting domain of a TEM provides an altered cell targeting capability that targets the molecule to a receptor other than the native Clostridial toxin receptor utilized by a naturally-occurring Clostridial toxin.
  • This re-targeted capability is achieved by replacing the naturally-occurring binding domain of a Clostridial toxin with a targeting domain having a binding activity for a non-Clostridial toxin receptor.
  • a TEM undergoes all the other steps of the intoxication process including internalization of the TEM/receptor complex into the cytoplasm, formation of the pore in the vesicle membrane and di-chain molecule, translocation of the enzymatic domain into the cytoplasm, and exerting a proteolytic effect on a component of the SNARE complex of the target cell.
  • Tonicity agent or “isotonic agent” means a low molecular weight excipient which is included in a lyophilized or liquid formulation to provide isotonicity.
  • a disaccharide such as trehalose or sucrose
  • a polyalcohol such as sorbitol or mannitol
  • a monosaccharide such as glucose
  • a salt such as sodium chloride
  • Topical administration excludes systemic administration of the neurotoxin. In other words, and unlike conventional therapeutic transdermal methods, topical administration of botulinum toxin does not result in significant amounts, such as the majority of, the neurotoxin passing into the circulatory system of the patient.
  • Treating means to alleviate (or to eliminate) at least one symptom of a condition or disorder, such as, for example, wrinkles, spasticity, depression, pain (such as, for example, headache pain), bladder overactivity, or the like, either temporarily or permanently.
  • the term “unit” or “U” refers to the LD 50 dose or the dose determined by a cell based potency assay (CBPA).
  • the LD 50 dose is defined as the amount of a Clostridial toxin active ingredient, Clostridial toxin complex or modified Clostridial toxin that killed 50% of the mice injected with the Clostridial toxin, Clostridial toxin complex or modified Clostridial toxin.
  • the CBPA dose is determined as described in U.S. Pat. No. 8,618,261, the assay details of which are incorporated by reference herein.
  • “Variant” means a clostridial neurotoxin, such as wild-type botulinum toxin serotype A, B, C, D, E, F or G, that has been modified by the replacement, modification, addition or deletion of at least one amino acid relative to wild-type botulinum toxin, which is recognized by a target cell, internalized by the target cell, and catalytically cleaves a SNARE (SNAP (Soluble NSF Attachment Protein) Receptor) protein in the target cell.
  • SNARE Soluble NSF Attachment Protein
  • a variant neurotoxin component can comprise a variant light chain of a botulinum toxin having one or more amino acids substituted, modified, deleted and/or added.
  • This variant light chain may have the same or better ability to prevent exocytosis, for example, the release of neurotransmitter vesicles.
  • the biological effect of a variant may be decreased compared to the parent chemical entity.
  • a variant light chain of a botulinum toxin type A having an amino acid sequence removed may have a shorter biological persistence than that of the parent (or native) botulinum toxin type A light chain.
  • the composition does not comprise a sugar or polyalcohol.
  • Sugar is defined in the next section.
  • polyalcohol is synonymous with “sugar alcohol,” “polyhydric alcohol,” and “polyol” and refers to a sugar derivative having an alcohol group (CH 2 OH) instead of the aldehyde group (CHO), such as, e.g., mannitol from mannose, xylitol from xylose, and lactitol from lactulose.
  • Non-limiting examples of polyols include, glycol, glycerol, arabitol, erythritol, xylitol, maltitol, sorbitol (gluctiol), mannitol, inositol, lactitol, galactitol (iditol), isomalt.
  • Other non-limiting examples of sugar excipients can be found in, e.g., Ansel, supra, (1999); Gennaro, supra, (2000); Hardman, supra, (2001); and Rowe, supra, (2003), each of which is hereby incorporated by reference in its entirety.
  • Certain embodiments of the present invention include a pharmaceutical composition
  • a pharmaceutical composition comprising (or consisting of, or consisting essentially of) a Clostridial toxin active ingredient such as a botulinum toxin, a disaccharide, a surfactant and an antioxidant.
  • Clostridial toxin active ingredient refers to a therapeutically effective concentration of a Clostridial toxin active ingredient, such as, e.g., a Clostridial toxin complex, a Clostridial toxin, a modified Clostridial toxin, or a re-targeted Clostridial toxin.
  • a botulinum toxin is a particularly preferred Clostridial toxin active ingredient for use in the invention.
  • terapéuticaally effective concentration is synonymous with “therapeutically effective amount,” “effective amount,” “effective dose,” and “therapeutically effective dose” and refers to the minimum dose of a Clostridial toxin active ingredient, which is most preferably a botulinum toxin, necessary to achieve the desired therapeutic effect and includes a dose sufficient to reduce a symptom associated with aliment being treated.
  • a therapeutically effective concentration of a Clostridial toxin active ingredient which is most preferably a botulinum toxin, reduces a symptom associated with the aliment being treated by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
  • a therapeutically effective concentration of a Clostridial toxin active ingredient which is most preferably a botulinum toxin, reduces a symptom associated with the aliment being treated by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
  • any amount of Clostridial toxin active ingredient which is most preferably a botulinum toxin, can be added in formulating a Clostridial toxin pharmaceutical compositions disclosed in the present specification, with the proviso that a therapeutically effective amount of the Clostridial toxin active ingredient is recoverable.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is at least 0.1 U/ml, at least 1.0 U/ml, at least 10 U/ml, at least 50 U/ml, at least 100 U/ml, at least 200 U/ml, or at least 1000 U/ml.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is at most 0.1 U/ml, at most 1.0 U/ml, at most 10 U/ml, at most 50 U/ml, at most 100 U/ml, at most 200 U/ml, or at most 1000 U/ml. In yet other aspects of this embodiment, the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is from about 0.1 U/ml to about 1000 U/ml, or about 1.0 U/ml to about 1000 U/ml.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is from about 0.001 U/ml to about 100 U/ml, about 0.01 U/ml to about 100 U/ml, about 0.1 U/ml to about 100 U/ml, or about 1.0 U/ml to about 100 U/ml.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is at least 1.0 ⁇ g, at least 10 ⁇ g, at least 100 ⁇ g, at least 1.0 ng, at least 10 ng, at least 100 ng, at least 1.0 ⁇ g, at least 10 ⁇ g, at least 100 ⁇ g, or at least 1.0 mg.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is at most 1.0 ⁇ g, at most 10 ⁇ g, at most 100 ⁇ g, at most 1.0 ng, at most 10 ng, at most 100 ng, at most 1.0 ⁇ g, at most 10 ⁇ g, at most 100 ⁇ g, or at most 1.0 mg.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is about 1.0 ⁇ g to about 10 ⁇ g, about 10 ⁇ g to about 10 ⁇ g, about 100 ⁇ g to about 10 ⁇ g, about 1.0 ng to about 10 ⁇ g, about 10 ng to about 10 ⁇ g, or about 100 ng to about 10 ⁇ g.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is about 1.0 ⁇ g to about 1.0 ⁇ g, about 10 ⁇ g to about 1.0 ⁇ g, about 100 ⁇ g to about 1.0 ⁇ g, about 1.0 ng to about 1.0 ⁇ g, about 10 ng to about 1.0 ⁇ g, or about 100 ng to about 1.0 ⁇ g.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is about 1.0 ⁇ g to about 5.0 ⁇ g, about 10 ⁇ g to about 5.0 ⁇ g, about 100 ⁇ g to about 5.0 ⁇ g, about 1.0 ng to about 5.0 ⁇ g, about 10 ng to about 5.0 ⁇ g, or about 100 ng to about 5.0 ⁇ g.
  • the amount of Clostridial toxin active ingredient, which is most preferably a botulinum toxin, added to the formulation is about 1.0 ⁇ g to about 10 ⁇ g, about 10 ⁇ g to about 10 ⁇ g, about 100 pg to about 10 ⁇ g, about 1.0 ng to about 10 ⁇ g, about 10 ng to about 10 ⁇ g, or about 100 ng to about 10 ⁇ g.
  • a Clostridial toxin pharmaceutical composition comprises a BoNT/A, a BoNT/B, a BoNT/C 1 , a BoNT/D, a BoNT/E, a BoNT/F, a BoNT/G, a BoNT mosaic, such as BoNT/DC, BoNT/CD and BoNT/FA, a TeNT, a BaNT, or a BuNT.
  • a Clostridial toxin pharmaceutical composition comprises a Clostridial toxin variant as the Clostridial toxin active ingredient.
  • a Clostridial toxin pharmaceutical composition comprises naturally-occurring Clostridial toxin variant or a non-naturally-occurring Clostridial toxin variant.
  • a Clostridial toxin pharmaceutical composition comprises a BoNT/A variant, a BoNT/B variant, a BoNT/C 1 variant, a BoNT/D variant, a BoNT/E variant, a BoNT/F variant, a BoNT/G variant, a TeNT variant, a BaNT variant, or a BuNT variant, where the variant is either a naturally-occurring variant or a non-naturally-occurring variant.
  • Clostridial toxin complex refers to a complex comprising a Clostridial toxin and associated NAPs, such as, e.g., a Botulinum toxin complex, a Tetanus toxin complex, a Baratii toxin complex, and a Butyricum toxin complex.
  • Non-limiting examples of Clostridial toxin complexes include those produced by a Clostridium botulinum , such as, e.g., a 900-kDa BoNT/A complex, a 500-kDa BoNT/A complex, a 300-kDa BoNT/A complex, a 500-kDa BoNT/B complex, a 500-kDa BoNT/C 1 complex, a 500-kDa BoNT/D complex, a 300-kDa BoNT/D complex, a 300-kDa BoNT/E complex, and a 300-kDa BoNT/F complex.
  • a Clostridium botulinum such as, e.g., a 900-kDa BoNT/A complex, a 500-kDa BoNT/A complex, a 300-kDa BoNT/A complex, a 500-kDa BoNT/B complex, a 500-kDa BoNT/C 1 complex, a 500-kD
  • Clostridial toxin complexes can be purified using the methods described in Schantz, supra, (1992); Hui Xiang et al., Animal Product Free System and Process for Purifying a Botulinum Toxin, U.S. Pat. No. 7,354,740, each of which is hereby incorporated by reference in its entirety.
  • Clostridial toxin complexes can be obtained from, e.g., List Biological Laboratories, Inc. (Campbell, Calif.), the Centre for Applied Microbiology and Research (Porton Down, U.K), Wako (Osaka, Japan), and Sigma Chemicals (St Louis, Mo.).
  • non-protein excipient refers to any excipient that is not a polypeptide comprising at least fifteen amino acids. It is envisioned that any non-protein excipient is useful in formulating a Clostridial toxin pharmaceutical compositions disclosed in the present specification, with the proviso that a therapeutically effective amount of the Clostridial toxin active ingredient, which is most preferably a botulinum toxin, is recovered using this non-protein excipient.
  • compositions provide, in part, a sugar.
  • sugar refers to a compound comprising one to 10 monosaccharide units, e.g., a monosaccharide, a disaccharide, a trisaccharide, and an oligosaccharide comprising four to ten monosaccharide units. It is envisioned that any sugar is useful in formulating a Clostridial toxin pharmaceutical compositions disclosed in the present specification, with the proviso that a therapeutically effective amount of the Clostridial toxin active ingredient, which is most preferably a botulinum toxin, is recovered using this sugar.
  • the sugar can function as a lyoprotector.
  • the sugar can function as a tonicity agent.
  • Monosaccharides are polyhydroxy aldehydes or polyhydroxy ketones with three or more carbon atoms, including aldoses, dialdoses, aldoketoses, ketoses and diketoses, as well as cyclic forms, deoxy sugars and amino sugars, and their derivatives, provided that the parent monosaccharide has a (potential) carbonyl group.
  • Monosacchrides include trioses, like glyceraldehyde and dihydroxyacetone; tetroses, like erythrose, erythrulose and threose; pentoses, like arabinose, lyxose, ribose, ribulose, xylose, xylulose; hexoses, like allose, altrose, fructose, fucose, galactose, glucose, gulose, idose, mannose, psicose, rhamnose, sorbose, tagatose, talose and trehalose; heptoses, like sedoheptulose and mannoheptulose; octooses, like octulose and 2-keto-3-deoxy-manno-octonate; nonoses like sialose; and decose.
  • trioses like glyceraldehyde and dihydroxyacetone
  • Oligosaccharides are compounds in which at least two monosaccharide units are joined by glycosidic linkages. According to the number of units, they are called disaccharides, trisaccharides, tetrasaccharides, pentasaccharides, hexoaccharides, heptoaccharides, octoaccharides, nonoaccharides, decoaccharides, etc.
  • An oligosaccharide can be unbranched, branched or cyclic.
  • Common disaccharides include, without limitation, sucrose, lactose, maltose, trehalose, cellobiose, gentiobiose, kojibiose, laminaribiose, mannobiose, melibiose, nigerose, rutinose, and xylobiose.
  • Common trisaccharides include, without limitation, raffinose, acarbose, maltotriose, and melezitose.
  • sugar excipients can be found in, e.g., Ansel, supra, (1999); Gennaro, supra, (2000); Hardman, supra, (2001); and Rowe, supra, (2003), each of which is hereby incorporated by reference in its entirety.
  • a Clostridial toxin pharmaceutical composition comprises a sugar.
  • a Clostridial toxin pharmaceutical composition comprises a monosaccharide.
  • a Clostridial toxin pharmaceutical composition comprises a disaccharide, a trisaccharide, a tetrasaccharide, a pentasaccharide, a hexoaccharide, a heptoaccharide, an octoaccharide, a nonoaccharide, or a decoaccharide.
  • a Clostridial toxin pharmaceutical composition comprises an oligosaccharide comprising two to ten monosaccharide units. Trehalose and sucrose are particularly preferred sugars for use in the invention.
  • any amount of sugar which is preferably trehalose or sucrose, is useful in formulating a Clostridial toxin pharmaceutical compositions disclosed in the present specification, with the proviso that a therapeutically effective amount of the Clostridial toxin active ingredient, which is most preferably a botulinum toxin, is recovered using this sugar amount.
  • the amount of sugar, which is preferably trehalose or sucrose, added to the formulation is about 0.1% (w/w), about 0.5% (w/w), about 1.0% (w/w), about 1.5% (w/w), about 2.0% (w/w), about 2.5% (w/w), about 3.0% (w/w), about 3.5% (w/w), about 4.0% (w/w), about 4.5% (w/w), about 5.0% (w/w), about 5.5% (w/w), about 6.0% (w/w), about 6.5% (w/w), about 7.0% (w/w), about 7.5% (w/w), about 8.0% (w/w), about 8.5% (w/w), about 9.0% (w/w), about 9.5% (w/w), about 10% (w/w), about 15% (w/w), about 20% (w/w), about 25% (w/w), about 30% (w/w), or about 35% (w/w).
  • the amount of sugar, which is preferably trehalose or sucrose, added to the formulation is at least 0.1% (w/w), at least 0.5% (w/w), at least 1.0% (w/w), at least 1.5% (w/w), at least 2.0% (w/w), at least 2.5% (w/w), at least 3.0% (w/w), at least 3.5% (w/w), at least 4.0% (w/w), at least 4.5% (w/w), at least 5.0% (w/w), at least 5.5% (w/w), at least 6.0% (w/w), at least 6.5% (w/w), at least 7.0% (w/w), at least 7.5% (w/w), at least 8.0% (w/w), at least 8.5% (w/w), at least 9.0% (w/w), at least 9.5% (w/w), at least 10% (w/w), at least 15% (w/w), at least 20% (w/w), at least 25% (w/w), at least 30% (w/w), or at least 35% (w/w), at least
  • the amount of sugar, which is preferably trehalose or sucrose, added to the formulation is at most 0.1% (w/w), at most 0.5% (w/w), at most 1.0% (w/w), at most 1.5% (w/w), at most 2.0% (w/w), at most 2.5% (w/w), at most 3.0% (w/w), at most 3.5% (w/w), at most 4.0% (w/w), at most 4.5% (w/w), at most 5.0% (w/w), at most 5.5% (w/w), at most 6.0% (w/w), at most 6.5% (w/w), at most 7.0% (w/w), at most 7.5% (w/w), at most 8.0% (w/w), at most 8.5% (w/w), at most 9.0% (w/w), at most 9.5% (w/w), at most 10% (w/w), at most 15% (w/w), at most 20% (w/w), at most 25% (w/w), at most 30% (w/w), or at most 35% (w/w), at most
  • the present Clostridial toxin pharmaceutical composition comprises a disaccharide, which is preferably trehalose or sucrose.
  • disaccharides include, without limitation, sucrose, lactose, maltose, trehalose, cellobiose, gentiobiose, kojibiose, laminaribiose, mannobiose, melibiose, nigerose, rutinose, and xylobiose.
  • the clostridial toxin pharmaceutical composition comprises sucrose.
  • the clostridial toxin pharmaceutical composition comprises trehalose.
  • the amount of disaccharide, which is preferably trehalose or sucrose, added to the formulation added to the formulation is about 0.1% (w/w), about 0.5% (w/w), about 1.0% (w/w), about 1.5% (w/w), about 2.0% (w/w), about 2.5% (w/w), about 3.0% (w/w), about 3.5% (w/w), about 4.0% (w/w), about 4.5% (w/w), about 5.0% (w/w), about 5.5% (w/w), about 6.0% (w/w), about 6.5% (w/w), about 7.0% (w/w), about 7.5% (w/w), about 8.0% (w/w), about 8.5% (w/w), about 9.0% (w/w), about 9.5% (w/w), about 10% (w/w), about 15% (w/w), about 20% (w/w), about 25% (w/w), about 30% (w/w), or about 35% (w/w).
  • compositions provide, in part, a surfactant.
  • surfactant refers to a natural or synthetic amphiphilic compound.
  • a surfactant can be non-ionic, zwitterionic, or ionic. It is envisioned that any surfactant is useful in formulating a Clostridial toxin pharmaceutical compositions disclosed in the present specification, with the proviso that a therapeutically effective amount of the Clostridial toxin active ingredient, which is most preferably a botulinum toxin, is recovered using this surfactant amount.
  • Non-limiting examples of surfactants include polysorbates like polysorbate 20 (TWEEN® 20), polysorbate 40 (TWEEN® 40), polysorbate 60 (TWEEN 60), polysorbate 61 (TWEEN® 61), polysorbate 65 (TWEEN® 65), polysorbate 80 (TWEEN® 80), and polysorbate 81 (TWEEN® 81); poloxamers (polyethylene-polypropylene copolymers), like Poloxamer 124 (PLURONIC® L44), Poloxamer 181 (PLURONIC® L61), Poloxamer 182 (PLURONIC® L62), Poloxamer 184 (PLURONIC® L64), Poloxamer 188 (PLURONIC® F68), Poloxamer 237 (PLURONIC® F87), Poloxamer 338 (PLURONIC® L108), Poloxamer 407 (PLURONIC® F127), polyoxyethyleneglycol dodecyl ethers, like BRIJ®
  • surfactant excipients can be found in, e.g., Ansel, supra, (1999); Gennaro, supra, (2000); Hardman, supra, (2001); and Rowe, supra, (2003), each of which is hereby incorporated by reference in its entirety.
  • Poloxamer 188 is a particularly preferred surfactant in the invention.
  • a Clostridial toxin pharmaceutical composition comprises a surfactant, which is preferably Poloxamer 188.
  • a Clostridial toxin pharmaceutical composition comprises a polysorbate, a poloxamer, a polyoxyethyleneglycol dodecyl ether, 2-dodecoxyethanol, polyoxyethylene octyl phenyl ether, sodium dodecyl sulfate, 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate, 3-[(3-Cholamidopropyl) dimethylammonio]-2-hydroxy-1-propanesulfonate, sucrose monolaurate; or sodium cholate.
  • any amount of surfactant which is preferably Poloxamer 188, is useful in formulating a Clostridial toxin pharmaceutical compositions disclosed in the present specification, with the proviso that a therapeutically effective amount of the Clostridial toxin active ingredient, which is preferably a botulinum toxin, is recovered using this surfactant amount.
  • the amount of surfactant, which is preferably Poloxamer 188, added to the formulation is about 0.01% (w/w), about 0.02% (w/w), about 0.03% (w/w), about 0.04% (w/w), about 0.05% (w/w), about 0.06% (w/w), about 0.07% (w/w), about 0.08% (w/w), about 0.09% (w/w), about 0.1% (w/w), about 0.5% (w/w), about 1.0% (w/w), about 1.5% (w/w), about 2.0% (w/w), about 2.5% (w/w), about 3.0% (w/w), about 3.5% (w/w), about 4.0% (w/w), about 4.5% (w/w), about 5.0% (w/w), about 5.5% (w/w), about 6.0% (w/w), about 6.5% (w/w), about 7.0% (w/w), about 7.5% (w/w), about 8.0% (w/w), about 8.5% (w/w), about 0.01% (w
  • the amount of surfactant, which is preferably Poloxamer 188, added to the formulation is at least 0.01% (w/w), at least 0.02% (w/w), at least 0.03% (w/w), at least 0.04% (w/w), at least 0.05% (w/w), at least 0.06% (w/w), at least 0.07% (w/w), at least 0.08% (w/w), at least 0.09% (w/w), at least 0.1% (w/w), at least 0.5% (w/w), at least 1.0% (w/w), at least 1.5% (w/w), at least 2.0% (w/w), at least 2.5% (w/w), at least 3.0% (w/w), at least 3.5% (w/w), at least 4.0% (w/w), at least 4.5% (w/w), at least 5.0% (w/w), at least 5.5% (w/w), at least 6.0% (w/w), at least 6.5% (w/w), at least 7.0% (w/w),
  • the amount of surfactant, which is preferably Poloxamer 188, added to the formulation is at most 0.01% (w/w), at most 0.02% (w/w), at most 0.03% (w/w), at most 0.04% (w/w), at most 0.05% (w/w), at most 0.06% (w/w), at most 0.07% (w/w), at most 0.08% (w/w), at most 0.09% (w/w), at most 0.1% (w/w), at most 0.5% (w/w), at most 1.0% (w/w), at most 1.5% (w/w), at most 2.0% (w/w), at most 2.5% (w/w), at most 3.0% (w/w), at most 3.5% (w/w), at most 4.0% (w/w), at most 4.5% (w/w), at most 5.0% (w/w), at most 5.5% (w/w), at most 6.0% (w/w), at most 6.5% (w/w), at most 7.0% (w/w/w),
  • the clostridial toxin pharmaceutical composition comprises a poloxamer, which is preferably Poloxamer 188.
  • Poloxamers which can be used with the present pharmaceutical composition include Poloxamer 124 (PLURONIC® L44), Poloxamer 181 (PLURONIC® L61), Poloxamer 182 (PLURONIC® L62), Poloxamer 184 (PLURONIC® L64), Poloxamer 188 (PLURONIC® F68), Poloxamer 237 (PLURONIC® F87), Poloxamer 338 (PLURONIC® L108), Poloxamer 407 (PLURONIC® F127).
  • poloxamer 188 may be more advantageous.
  • the clostridial toxin pharmaceutical composition comprises a polysorbate.
  • Polysorbates which can be used with the present pharmaceutical composition includes polysorbate 20 (TWEEN® 20), polysorbate 40 (TWEEN® 40), polysorbate 60 (TWEEN® 60), polysorbate 61 (TWEEN® 61), polysorbate 65 (TWEEN® 65), polysorbate 80 (TWEEN® 80), and polysorbate 81 (TWEEN® 81).
  • polysorbate 20 may be more advantageous than some other polysorbates.
  • antioxidants include, without limitation, methionine, cysteine, N-acetyl-cysteine (NAC), sodium metabisulfite, sodium thiosulfate, butylated hydroxyanisole, butylated hydroxytoluene, vitamin E and analogs including Trolox C; chelators such as EDTA (ethylene diamine tetraacetic acid sodium salt), EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid), DTPA (diethylenetriaminepentaacetic acid), analogs or derivatives thereof, and combinations thereof.
  • EDTA ethylene diamine tetraacetic acid sodium salt
  • EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid
  • DTPA diethylenetriaminepentaacetic acid
  • Methionine and NAC are particularly preferred antioxidants for use in the invention.
  • NAC is particularly preferably used together with EDTA in certain formulations of the invention.
  • NAC is the sole antioxidant used.
  • methionine is the sole antioxidant used.
  • the amount of antioxidant, which is preferably methionine or NAC, added to the formulation ranges from about 0.01% (w/w) to about 0.10% (w/w).
  • EDTA is preferably added in an amount from about 0.01% (w/w) to about 0.10% (w/w).
  • a Clostridial toxin pharmaceutical composition disclosed in the present specification can optionally include, without limitation, other pharmaceutically acceptable components (or pharmaceutical components), including, without limitation, buffers, preservatives, tonicity adjusters, salts, antioxidants, osmolality adjusting agents, emulsifying agents, sweetening or flavoring agents, and the like.
  • buffers include, without limitation, acetate buffers, borate buffers, citrate buffers, phosphate buffers, neutral buffered saline, and phosphate buffered saline. Histidine is a particularly preferred buffer.
  • an effective pH level is at least about pH 5.0, at least about pH 5.5, at least about pH 6.0, at least about pH 6.5, at least about pH 7.0 or at about about pH 7.5.
  • an effective pH level is at most about pH 5.0, at most about pH 5.5, at most about pH 6.0, at most about pH 6.5, at most about pH 7.0 or at most about pH 7.5.
  • an effective pH level is about pH 5.0 to about pH 8.0, an effective pH level is about pH 5.0 to about pH 7.0, an effective pH level is about pH 5.0 to about pH 6.0, is about pH 5.5 to about pH 8.0, an effective pH level is about pH 5.5 to about pH 7.0, an effective pH level is about pH 5.5 to about pH 5.0, is about pH 5.5 to about pH 7.5, an effective pH level is about pH 5.5 to about pH 6.5.
  • An effective pH of 5.5 to 6.0 is particularly preferred.
  • the pharmaceutical compositions disclosed herein can have a pH of between about 5 and 8 when reconstituted or upon injection.
  • the composition will have a pH below 8, such as, for example, 7.9, or 7.8, or 7.7, or 7.6, or 7.5, or 7.4, or 7.3, or 7.2, or 7.1, or 7.0, or 6.9, or 6.8, or 6.7, or 6.6, or 6.5, or 6.4, or 6.3, or 6.2, or 6.1, or 6.0, or 5.9, or 5.8, or 5.7, or 5.6, or 5.5, or 5.4, or 5.3, or 5.2, or 5.1, or the like.
  • the pH ranges from 5 to 7.
  • a pH of 5.5 to 6.5 is preferred and a pH of 5.5 to 6.0 is particularly preferred.
  • any concentration of a buffer can be useful in formulating a Clostridial toxin pharmaceutical composition, with the proviso that a therapeutically effective amount of the Clostridial toxin active ingredient, which is most preferably a botulinum toxin, is recovered using this effective concentration of buffer, which is preferably histidine.
  • an effective concentration of buffer, which is preferably histidine is at least 0.1 mM, at least 0.2 mM, at least 0.3 mM, at least 0.4 mM, at least 0.5 mM, at least 0.6 mM, at least 0.7 mM, at least 0.8 mM, or at least 0.9 mM.
  • an effective concentration of buffer which is preferably histidine, is at least 1.0 mM, at least 2.0 mM, at least 3.0 mM, at least 4.0 mM, at least 5.0 mM, at least 6.0 mM, at least 7.0 mM, at least 8.0 mM, or at least 9.0 mM.
  • an effective concentration of buffer, which is preferably histidine is at least 10 mM, at least 20 mM, at least 30 mM, at least 40 mM, at least 50 mM, at least 60 mM, at least 70 mM, at least 80 mM, or at least 90 mM.
  • an effective concentration of buffer which is preferably histidine, is at least 100 mM, at least 200 mM, at least 300 mM, at least 400 mM, at least 500 mM, at least 600 mM, at least 700 mM, at least 800 mM, or at least 900 mM.
  • an effective concentration of buffer, which is preferably histidine is at most 0.1 mM, at most 0.2 mM, at most 0.3 mM, at most 0.4 mM, at most 0.5 mM, at most 0.6 mM, at most 0.7 mM, at most 0.8 mM, or at most 0.9 mM.
  • an effective concentration of buffer which is preferably histidine, is at most 1.0 mM, at most 2.0 mM, at most 3.0 mM, at most 4.0 mM, at most 5.0 mM, at most 6.0 mM, at most 7.0 mM, at most 8.0 mM, or at most 9.0 mM.
  • an effective concentration of buffer, which is preferably histidine is at most 10 mM, at most 20 mM, at most 30 mM, at most 40 mM, at most 50 mM, at most 60 mM, at most 70 mM, at most 80 mM, or at most 90 mM.
  • an effective concentration of buffer which is preferably histidine, is at most 100 mM, at most 200 mM, at most 300 mM, at most 400 mM, at most 500 mM, at most 600 mM, at most 700 mM, at most 800 mM, or at most 900 mM.
  • an effective concentration of buffer which is preferably histidine, is about 0.1 mM to about 900 mM, 0.1 mM to about 500 mM, 0.1 mM to about 100 mM, 0.1 mM to about 90 mM, 0.1 mM to about 50 mM, 1.0 mM to about 900 mM, 1.0 mM to about 500 mM, 1.0 mM to about 100 mM, 1.0 mM to about 90 mM, or 1.0 mM to about 50 mM.
  • the concentration of the buffer which is most preferably histidine, is preferably 20 mM.
  • Embodiments of the invention can be practiced with a composition that comprises a plurality of botulinum toxin serotypes, such as botulinum toxin serotypes selected from the group consisting of botulinum toxin serotypes A, B, C 1 D, E, F, G and mosaic.
  • botulinum toxin serotypes selected from the group consisting of botulinum toxin serotypes A, B, C 1 D, E, F, G and mosaic.
  • purified botulinum toxins can be used.
  • modified botulinum toxins may be used.
  • the Clostridial toxin pharmaceutical composition of the invention can be formulated as a lyophilized (i.e. freeze dried) or vacuum dried powder which can be reconstituted with a suitable fluid, such as saline or water, prior to administration to a patient.
  • a suitable fluid such as saline or water
  • the pharmaceutical composition can be formulated as an aqueous solution or suspension.
  • the solid Clostridial toxin pharmaceutical composition of the invention comprises a botulinum toxin, a tonicity agent, a poloxamer and/or a polysorbate and an antioxidant.
  • the Clostridial toxin pharmaceutical composition comprises a botulinum toxin.
  • the Clostridial toxin pharmaceutical composition comprises trehalose.
  • the Clostridial toxin pharmaceutical composition comprises poloxamer 188 or polysorbate 20.
  • the composition comprises EDTA, EGTA, DTPA, or analogs thereof.
  • the composition comprises methionine and/or NAC.
  • the composition further comprises EDTA, EGTA, DTPA, or analogs thereof.
  • the composition further comprises a buffering agent.
  • the composition comprises histidine buffer.
  • the relative weight amounts of trehalose, poloxamer and methionine are within the following ranges respectively: 1 to 10%; 0.5 to 5% and 0.1 to 0.3%.
  • the relative weight amounts of trehalose, polysorbate and methionine are within the following ranges respectively: 1 to 10%; 0.02% to 0.06%; and 0.1 to 0.3%.
  • the relative weight amount of EDTA or an EDTA analog is from about 0.01 to 0.10%.
  • the relative weight amount of NAC ranges from 0.01 to 0.5%.
  • the Clostridial toxin pharmaceutical composition is formulated as a solid (i.e lyophilized or vacuum dried) composition.
  • the solid Clostridial pharmaceutical composition comprises a lyoprotector.
  • the preferred lyoprotector includes sucrose, trehalose, mannitol, sorbitol or combinations thereof.
  • the solid pharmaceutical composition comprises NAC in a relative weight amount of 0.01 to 0.05%.
  • the pharmaceutical composition further comprises EDTA, EGTA, DTPA, or analogs thereof.
  • the solid pharmaceutical composition comprises methionine and EDTA or an EDTA analog.
  • the Clostridial toxin pharmaceutical composition is formulated as a liquid.
  • the liquid pharmaceutical composition comprises NAC in a relative weight amount of 0.1 to 0.5%.
  • the liquid pharmaceucial composition comprises NAC and EDTA, EGTA, DTPA, or analogs thereof.
  • the liquid pharmaceutical composition comprises histidine buffer.
  • the liquid pharmaceutical composition has a pH from 5 to 7.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising:
  • poloxamer 188 with either methionine or N-Acetyl-cysteine in the present invention is preferred because of the synergistic effect on the stability of the compositions caused by the combination of this particular surfactant with either of these antioxidants.
  • composition may further comprise trehalose or sucrose.
  • Trehalose is preferred over sucrose for the solid compositions.
  • composition may optionally also include NaCl.
  • NaCl may particularly preferably be included in compositions comprising botulinum toxin, trehalose or sucrose, poloxamer 188, and methionine, and is particularly preferably included in liquid compositions comprising botulinum toxin, trehalose or sucrose, poloxamer 188, and methionine.
  • NaCl may function as a tonicity agent in a reconstitution vehicle.
  • the composition may optionally include EDTA, EGTA, DTPA, or analogs thereof.
  • EDTA may be included in compositions comprising botulinum toxin, trehalose or sucrose, poloxamer 188 and methionine, and is preferably included in liquid compositions comprising botulinum toxin, trehalose or sucrose, poloxamer 188 and methionine.
  • EDTA, EGTA, DTPA, or analogs thereof may also be included in compositions comprising botulinum toxin, trehalose or sucrose, poloxamer 188 and NAC; and is particularly preferably included in liquid compositions comprising botulinum toxin, trehalose or sucrose, poloxamer 188 and NAC.
  • the combination of EDTA and NAC is particularly preferred as it has a synergistic stabilising effect on the compositions of the invention.
  • the relative weight amounts (%, w/w) of trehalose or sucrose, poloxamer 188, methionine, and NaCl where present, and EDTA where present are preferably within the following ranges:
  • Trehalose or sucrose 1 to 10 poloxamer 188 0.5 to 5 methionine 0.1 to 0.3 NaCl 0.1 to 10 EDTA 0.01 to 0.1.
  • Such compositions may be both liquid and solid formulations.
  • the sugar is trehalose.
  • compositions preferably comprise a buffer.
  • the buffer is preferably histidine, and the concentration of histidine is preferably 20 mM when the composition is a liquid composition.
  • the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is most preferably in the range 5.5-6.
  • the histidine is preferably comprised in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • the relative weight amounts (%, w/w) of trehalose, poloxamer 188, and methionine are:
  • the composition labelled as a) above may be a solid composition, which is preferably lyophilised.
  • This composition also preferably comprises a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in the solid composition in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • the histidine may be present as a pure substance, the acid salt of histidine (e.g. Histidine HCl), a hydrate of an acid salt of the histidine, or a mix of any of the foregoing.
  • histidine base may be present in an amount of 1.43 mg/mL (or 0.14% w/w) together with histidine hydrochloride in an amount of 2.26 mg/mL (or 0.23% w/w).
  • the total concentration of histidine species is then 0.37% w/w.
  • the solid composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • This solid composition most preferably has either of the following compositions:
  • the composition is a solid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, methionine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • the solid composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl may be present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the composition labelled as a) above may also be a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 6.
  • the composition is a liquid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, methionine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of trehalose, poloxamer 188 and methionine are:
  • trehalose 7 to 9 poloxamer 188 0.5 to 0.7 methionine 0.15 to 0.25; and are preferably trehalose 8 poloxamer 188 0.6 methionine 0.2.
  • the composition labelled as b) above is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 5.5.
  • the composition is a liquid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, methionine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of trehalose, poloxamer 188, methionine, and NaCl are:
  • the composition labelled as c) above is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, and the pH is more preferably in the range 5.5-6.5, the pH is yet more preferably in the range 5.5-6, and is most preferably 5.5.
  • the composition is a liquid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, methionine, NaCl and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of trehalose, poloxamer 188, methionine, and EDTA are:
  • the composition labelled as d) above is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 6.
  • the composition is a liquid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, methionine, EDTA and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of trehalose or sucrose, poloxamer 188, N-Acetyl-cysteine, and EDTA where present are preferably within the following ranges
  • compositions may be both liquid and solid formulations, and are preferably liquid compositions.
  • the sugar is trehalose.
  • compositions preferably comprise a buffer.
  • the buffer is preferably histidine, and the concentration of histidine is preferably 20 mM when the composition is a liquid composition.
  • the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is most preferably in the range 5.5-6.
  • the histidine is preferably comprised in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • the relative weight amounts (%, w/w) of trehalose, poloxamer 188, N-Acetyl-cysteine and EDTA are:
  • this composition is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 6.
  • the composition is a liquid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, N-Acetyl-cysteine, EDTA and a buffer, wherein these components are preferably present in the amounts defined above.
  • the EDTA is an optional component in the N-Acetyl-cysteine containing compositions of the invention.
  • the relative weight amounts (%, w/w) of trehalose, poloxamer 188, and N-Acetyl-cysteine may be:
  • the relative weight amounts (%, w/w) of components in the EDTA-free compositions are:
  • this EDTA-free composition is preferably a solid composition, which is preferably lyophilised.
  • This composition also preferably comprises a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in the solid composition in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • the histidine may be present as a pure substance, the acid salt of histidine, a hydrate of an acid salt of the histidine, or a mix of any of the foregoing.
  • histidine base may be present in an amount of 1.43 mg/mL (or 0.14% w/w) together with histidine hydrochloride in an amount of 2.26 mg/mL (or 0.23% w/w).
  • the total concentration of histidine species is then 0.37% w/w.
  • the composition is a solid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, N-Acetyl-cysteine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • the composition of the invention does not comprise a sugar or polyalcohol.
  • the composition comprises botulinum toxin, poloxamer 188, and methionine or N-Acetyl-cysteine, but no sugar or polyalcohol.
  • the composition comprises N-Acetyl-cysteine, it is preferred that it additionally also contains EDTA.
  • the relative weight amounts (%, w/w) of poloxamer 188, and methionine are preferably within the following ranges:
  • poloxamer 188 0.5 to 5 methionine 0.1 to 0.3.
  • the relative weight amounts (%, w/w) of poloxamer 188, and N-Acetyl-cysteine and EDTA are preferably within the following ranges:
  • poloxamer 188 0.5 to 5 N-Acetyl-cysteine 0.01 to 0.5 EDTA 0.01 to 0.1.
  • compositions are preferably liquid formulations.
  • the relative weight amounts (%, w/w) of poloxamer 188 and methionine are:
  • compositions are preferably liquid compositions.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 6.
  • These compositions may also include NaCl. NaCl may be included in a relative weight amount of 0.5 to 1.5% (w/w), more preferably 0.9% (w/w).
  • the composition is a liquid composition consisting of one or more botulinum toxins, poloxamer 188, methionine, and a buffer, and optionally NaCl, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of poloxamer 188 and N-Acetyl-cysteine are:
  • compositions are preferably liquid compositions.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 6.
  • These compositions may also include NaCl. NaCl may be included in a relative weight amount of 0.5 to 1.5% (w/w), more preferably 0.9% (w/w).
  • the composition is a liquid composition consisting of one or more botulinum toxins, poloxamer 188, N-Acetyl-cysteine, a buffer, and optionally EDTA, and optionally NaCl, wherein these components are preferably present in the amounts defined above.
  • composition which does not comprise a sugar or polyalcohol described above may comprise Tween-20 in the place of poloxamer-188.
  • Such compositions may comprise Tween-20 in an amount of 0.01 to 0.1% (w/w), more preferably 0.02 to 0.06% (w/w), and most preferably 0.04% (w/w).
  • the relative weight amounts (%, w/w) of sucrose, poloxamer 188, and methionine are:
  • the composition labelled as a′) above may be a solid composition, which is preferably lyophilised.
  • This composition also preferably comprises a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in the solid composition in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • the histidine may be present as a pure substance, the acid salt of histidine (e.g. Histidine HCl), a hydrate of an acid salt of the histidine, or a mix of any of the foregoing.
  • histidine base may be present in an amount of 1.43 mg/mL (or 0.14% w/w) together with histidine hydrochloride in an amount of 2.26 mg/mL (or 0.23% w/w).
  • the total concentration of histidine species is then 0.37% w/w.
  • This solid composition most preferably has either of the following compositions:
  • the composition is a solid composition consisting of one or more botulinum toxins, sucrose, poloxamer 188, methionine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • the solid composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl may be present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the composition labelled as a′) above may also be a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 6.
  • the composition is a liquid composition consisting of one or more botulinum toxins, sucrose, poloxamer 188, methionine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of sucrose, poloxamer 188 and methionine are:
  • sucrose 7 to 9 poloxamer 188 0.5 to 0.7 methionine 0.15 to 0.25; and are preferably sucrose 8 poloxamer 188 0.6 methionine 0.2.
  • the composition labelled as b′) above is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 5.5.
  • the composition is a liquid composition consisting of one or more botulinum toxins, sucrose, poloxamer 188, methionine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of sucrose, poloxamer 188, methionine, and NaCl are:
  • the composition labelled as c′) above is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 5.5.
  • the composition is a liquid composition consisting of one or more botulinum toxins, sucrose, poloxamer 188, methionine, NaCl and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of sucrose, poloxamer 188, methionine, and EDTA are:
  • the composition labelled as d′) above is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is more preferably in the range 5.5-6, and is most preferably 6.
  • the composition is a liquid composition consisting of one or more botulinum toxins, sucrose, poloxamer 188, methionine, EDTA and a buffer, wherein these components are preferably present in the amounts defined above.
  • the relative weight amounts (%, w/w) of sucrose, poloxamer 188, N-Acetyl-cysteine and EDTA are:
  • this composition is preferably a liquid composition.
  • the composition preferably comprises a buffer, wherein the buffer is preferably histidine.
  • the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and the pH is yet more preferably in the range 5.5-6, and is most preferably 6.
  • the composition is a liquid composition consisting of one or more botulinum toxins, sucrose, poloxamer 188, N-Acetyl-cysteine, EDTA and a buffer, wherein these components are preferably present in the amounts defined above.
  • the EDTA is an optional component in the N-Acetyl-cysteine containing compositions of the invention.
  • the relative weight amounts (%, w/w) of sucrose, poloxamer 188, and N-Acetyl-cysteine may be:
  • the relative weight amounts (%, w/w) of components in the EDTA-free compositions are:
  • this EDTA-free composition is preferably a solid composition, which is preferably lyophilised.
  • This composition also preferably comprises a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in the solid composition in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • the histidine may be present as a pure substance, the acid salt of histidine, a hydrate of an acid salt of the histidine, or a mix of any of the foregoing.
  • histidine base may be present in an amount of 1.43 mg/mL (or 0.14% w/w) together with histidine hydrochloride in an amount of 2.26 mg/mL (or 0.23% w/w).
  • the total concentration of histidine species is then 0.37% w/w.
  • the composition is a solid composition consisting of one or more botulinum toxins, sucrose, poloxamer 188, N-Acetyl-cysteine, and a buffer, wherein these components are preferably present in the amounts defined above.
  • compositions of the invention may be a liquid composition, in which case the composition preferably comprises a buffer.
  • This buffer is preferably histidine, and the concentration of histidine is preferably 20 mM.
  • the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and is most preferably in the range 5.5-6.
  • compositions of the invention may also be a solid composition, which is preferably lyophilised.
  • the composition may further comprise a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • composition of the invention comprises no animal-derived protein.
  • compositions comprising a botulinum toxin, poloxamer 188, and methionine or N-Acetyl-cysteine may also further comprise ethylene diamine tetraacetic acid sodium salt (EDTA) or an EDTA analog.
  • EDTA ethylene diamine tetraacetic acid sodium salt
  • the relative weight amount (%, w/w) of EDTA in these compositions may be in the range from about 0.01 to 0.10.
  • Antioxidant refers to any compound which protects an active ingredient from reaction with oxygen. Antioxidants can be broadly divided into three categories:
  • antioxidants which react with oxygen more readily than a particular active ingredient and therefore can scavenge oxygen.
  • this type of antioxidant is preferably ascorbic acid;
  • chain terminators which react with free radicals and peroxides to prevent propagation of radical chains.
  • methionine, cysteine, N-Acetyl-cysteine and BHT are preferable chain terminators; and
  • chelating agents which reduce catalytic activity of transition metals by forming complexes with the metals.
  • EDTA, EGTA, and DTPA are preferred chelating agents.
  • compositions define the invention by reference to the general or specific types of antioxidant discussed in the previous paragraph. These compositions may all optionally comprise a buffer.
  • the buffer is preferably histidine, and the concentration of histidine is preferably 20 mM, and the pH is preferably in the range 5-7, and the pH is still more preferably in the range 5.5-6.5, and the pH is most preferably in the range 5.5-6.
  • the buffer is preferably histidine, and the histidine is preferably comprised in a relative weight amount of 0.1 to 0.5 (% w/w), and is more preferably contained in a relative weight amount of 0.3-0.4% (w/w).
  • all of the following compositions may comprise NaCl.
  • the invention also relates to a liquid pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a poloxamer; (iii) a chelating agent; and (iv) a sacrificial antioxidant.
  • the chelating agent is EDTA, EGTA or DTPA and the sacrificial antioxidant is ascorbic acid.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the invention also relates to a liquid pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a poloxamer; (iii) a chelating agent; and/or (iv) a chain terminator.
  • the chelating agent is EDTA and the chain terminator is N-acetyl-cysteine. In another preferred embodiment, the chelating agent is EDTA and the chain terminator is Butylated hydroxytoluene (BHT). In another preferred embodiment, the chelating agent is EDTA and the chain terminator is methionine. In another preferred embodiment of this liquid pharmaceutical composition, the chelating agent is DTPA and the chain terminator is N-acetyl-cysteine. In another preferred embodiment, the chelating agent is DTPA and the chain terminator is BHT. In another preferred embodiment, the chelating agent is DTPA and the chain terminator is methionine.
  • the chelating agent is EGTA and the chain terminator is N-acetyl-cysteine.
  • the chelating agent is EGTA and the chain terminator is BHT.
  • the chelating agent is EGTA and the chain terminator is methionine.
  • the liquid composition includes a chain terminator and not a chelating agent; wherein the chain terminator is NAC.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the invention also relates to a liquid pharmaceutical composition
  • a liquid pharmaceutical composition comprising:
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the poloxamer-188 and methionine are preferably present in the amounts defined above with respect to the compositions which do not comprise a sugar or a polyalcohol.
  • the invention also relates to a liquid pharmaceutical composition
  • a liquid pharmaceutical composition comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof; (ii) a poloxamer; and (iii) methionine.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the poloxamer-188 and methionine are preferably present in the amounts defined above with respect to the compositions which comprise a sugar or a polyalcohol.
  • the invention also preferably relates to a liquid pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a sacrificial antioxidant.
  • the chelating agent is preferably EDTA, EGTA or DTPA and the sacrificial antioxidant is preferably ascorbic acid.
  • the clostridial toxin is preferably a botulinum toxin, the poloxamer is preferably poloxamer-188 and the polysorbate is preferably polysorbate-20 or 80.
  • the invention also preferably relates to a liquid pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a chain terminator.
  • the chelating agent is preferably EDTA, EGTA or DTPA and the chain terminator is preferably NAC.
  • the clostridial toxin is preferably a botulinum toxin, the poloxamer is preferably poloxamer-188 and the polysorbate is preferably polysorbate-20 or 80.
  • the invention also preferably relates to a liquid pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a tonicity agent selected from trehalose, sucrose, NaCl and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a chain terminator.
  • the chelating agent is preferably EDTA, EGTA or DTPA and the chain terminator is preferably NAC.
  • the clostridial toxin is preferably a botulinum toxin, the poloxamer is preferably poloxamer-188 and the polysorbate is preferably polysorbate-20 or 80.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a lyoprotectant selected from trehalose, sucrose, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a sacrificial antioxidant.
  • the chelating agent is preferably EDTA, EGTA or DTPA and the sacrificial antioxidant is preferably ascorbic acid.
  • the clostridial toxin is preferably a botulinum toxin
  • the poloxamer is preferably poloxamer-188
  • the polysorbate is preferably polysorbate-20 or 80.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a lyoprotectant selected from trehalose, sucrose, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a chain terminator.
  • the chelating agent is preferably EDTA, EGTA or DTPA and the chain terminator is preferably NAC.
  • the clostridial toxin is preferably a botulinum toxin
  • the poloxamer is preferably poloxamer-188
  • the polysorbate is preferably polysorbate-20 or 80.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a lyoprotectant selected from trehalose, sucrose, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; and (iv) a chain terminator.
  • the chain terminator is preferably NAC or methionine.
  • the clostridial toxin is preferably a botulinum toxin
  • the poloxamer is preferably poloxamer-188
  • the polysorbate is preferably polysorbate-20 or 80.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, or combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; (iv) a chelating agent; and (v) a chain terminator.
  • the chelating agent is preferably EDTA, EGTA or DTPA and the chain terminator is preferably NAC.
  • the clostridial toxin is preferably a botulinum toxin
  • the poloxamer is preferably poloxamer-188
  • the polysorbate is preferably polysorbate-20 or 80.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; (iv) a chelating agent; and (v) a sacrificial antioxidant.
  • the chelating agent is preferably EDTA, EGTA or DTPA and the sacrificial antioxidant is preferably ascorbic acid.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; (iv) a chelating agent; and (v) a chain terminator.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; and (iv) a chain terminator.
  • the chain terminator is N-Acetyl-cysteine.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, or combinations thereof; (iii) a poloxamer; and (iv) methionine.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a lyoprotector selected from trehalose, sucrose, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; and (iv) at least two types of antioxidant selected from the list of chelating agents, chain terminators, and sacrificial antioxidants.
  • the clostridial toxin is preferably a botulinum toxin
  • the poloxamer is preferably poloxamer-188
  • the polysorbate is preferably polysorbate-20 or 80.
  • the chelating agents are preferably EDTA, EGTA or DTPA
  • the sacrificial antioxidant is preferably ascorbic acid
  • the chain terminators are preferably methionine, cysteine, NAC, or BHT.
  • the two types of antioxidants preferably include combinations of ascorbic acid with methionine, cysteine, NAC, or BHT.
  • the two types of antioxidants also preferably include combinations of ascorbic acid with EDTA, EGTA or DTPA.
  • the two types of antioxidants also preferably include the combinations of EDTA with methionine, cysteine, NAC, or BHT.
  • the two types of antioxidant also preferably include the combinations of DTPA with methionine, cysteine, NAC, or BHT.
  • the two types of antioxidant also preferably include the combinations of EGTA with methionine, cysteine, NAC, or BHT.
  • the lyophilized composition is reconstituted with a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof.
  • the lyophilized composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl is present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, or glucose; (iii) a poloxamer; (iv) a chelating agent; and (v) a chain terminator.
  • the chelating agent is EDTA
  • the chain terminator is N-Acetyl-cysteine or methionine.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the invention also relates to a lyophilized pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) trehalose, sucrose, mannitol, sorbitol, or glucose; (iii) a poloxamer; and (v) a chain terminator.
  • the chain terminator is N-Acetyl-cysteine or methionine.
  • the clostridial toxin is preferably a botulinum toxin and the poloxamer is preferably poloxamer-188.
  • the invention also relates to a liquid pharmaceutical composition, comprising:
  • a Clostridial toxin (i) a Clostridial toxin; (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate, and combinations thereof; and (iv) at least two types of antioxidant selected from the list of chelating agents, chain terminators, and sacrificial antioxidants.
  • a Clostridial toxin (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof; (iii) a surfactant selected from a poloxamer, a polysorbate, and combinations thereof; and (iv) at least two types of antioxidant selected from the list of chelating agents, chain terminators, and sacrificial antioxidants.
  • the clostridial toxin is preferably a botulinum toxin
  • the poloxamer is preferably poloxamer-188
  • the polysorbate is preferably polysorbate-20 or 80.
  • the chelating agents are preferably EDTA, EGTA or DTPA
  • the sacrificial antioxidant is preferably ascorbic acid
  • the chain terminators are preferably methionine, cysteine, NAC, or BHT.
  • the two types of antioxidants preferably include combinations of ascorbic acid with methionine, cysteine, NAC, or BHT.
  • the two types of antioxidants also preferably include combinations of ascorbic acid with EDTA, EGTA or DTPA.
  • the two types of antioxidants also preferably include the combinations of EDTA with methionine, cysteine, NAC, or BHT.
  • the two types of antioxidant also preferably include the combinations of DTPA with methionine, cysteine, NAC, or BHT.
  • the two types of antioxidant also preferably include the combinations of EGTA with methionine, cysteine, NAC, or BHT.
  • the invention provides methods of treating diseases, disorders, conditions, and the like, comprising the step of administering a pharmaceutical formulation of the invention to a subject in need thereof in an amount sufficient to produce improved patient function.
  • the diseases are of a neuromuscular nature, such as, for example, those diseases that affect muscles and nerve control thereof, such as, for example, overactive bladder, and the like.
  • the compositions of the invention are used in the treatment of cardiac arrhythmia.
  • certain embodiments relate to the treatment of pain, such as, for example, treatment of headache pain, or back pain, or muscle pain, or the like.
  • methods of the invention encompass the treatment of psychological disorders, including, for example, depression, anxiety, and the like.
  • the compositions of the invention are used in the treatment of depression.
  • composition is used in the treatment of depression, it is preferably used to treat adults with moderate to severe major depressive disorder (MDD) either single episode or recurrent, wherein this diagnosis is based upon the Diagnostic and Statistical Manual of Mental Disorders Text Edition, published in 2000 (DSM-IV-TR).
  • MDD moderate to severe major depressive disorder
  • DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders Text Edition
  • the composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl may be present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the composition is preferably administered in a single treatment session.
  • the dosage is preferably a total dose of 30 Units or 50 Units. These dosages are preferably administered in divided injection into 6 (for the 30 units dosage) or 8 (for the 50 Units dosage) injection sites into the glabellar region of the forehead, preferably into the procerus and corrugator muscles. This treatment may be repeated in 3 to 6 months intervals.
  • One advantage of the use of this method is that the patients treated with this composition show an improvement in the clinic Montgomery-Asberg Depression Rating scale. In addition, these patients also have improved clinic CGI-S scores (Clinical Global Impression of Change scores), and clinic HAM-D17 total scores (Hamilton Rating Scale for Depression).
  • compositions and methods of the invention can be useful for the treatment, reduction of symptoms, and/or prevention of, for example, achalasia, anal fissure, anismus, blepharospasm, cerebral palsy, cervical dystonia, cervicogenic headache, hemifacial spasm, dyshidrotic eczema, dysphagia, dysphonia, esophageal dysmotility, esophageal muscular ring, esotropia (infantile), eyelift, facial myokemia, gait disturbances (idiopathic toe-walking), generalized dystonia, hemifacial spasm, hyperfunctional facial lines (glabellar, forehead, crows' feet, down-turned angles of the mouth), hyperhidrosis, incontinence (idiopathic or neurogenic), medication overuse headache, migraine headache, myoclonus, muscle mass or activity reduction, involving, for example, the masseter or the like, myofascial pain syndrome, obstructive
  • composition is used in the treatment of cardiac arrhythmia
  • the patient is typically undergoing cardiac surgery.
  • the formulation used in the treatment may be any of the compositions of the invention. However, the formulation is preferably based on the lyophilized formulation described in Table A, which is taken up into solution for administration.
  • Table A Raw Material Concentration, Quantity per (Ingredient) w/w vial Function Botulinum 1200 U/mL 200 U Drug Substance toxin type A Trehalose 80 mg/mL 16 mg Lyo Protectant P188 40 mg/mL 8 mg Surfactant L-methionine 2 mg/mL 0.4 mg Antioxidant L-Histidine 1.430 mg/mL 0.286 mg Buffer L-Histidine HCl, 2.263 mg/mL 0.453 mg Buffer Monohydrate Water QS Adjust QS Adjust Solvent, removed by freeze-drying
  • the composition is reconstituted with a reconstitution vehicle comprising NaCl prior to administration to a patient.
  • NaCl may be present in an amount of 0.9% (w/w) in the reconstitution vehicle.
  • the mode of administration of the composition is by one time injection into the major epicardial fat pads of the heart.
  • the dosage used is 25 U per epicardial fat pad (125 U total dose) or 50 U per epicardial fat pad (250 U total dose).
  • One advantage of the use of this method is that the incidence of atrial fibrillation (AF) as measured by ECG through week 4 can be reduced.
  • Other advantages include: a reduction in the length of hospital stay; reduction in the length of stay in ICU; reduced rehospitalization rate of patients; reduced anticoagulant medication use; and reduced need for interventional procedures for Post Operative Atrial fibrillation (POAF), such as ablation, pacemaker implantation, electrical or pharmacologic cardioversion.
  • POAF Post Operative Atrial fibrillation
  • patients are limited to a maximum of 360 U of botulinum toxin administered over any 90-day period.
  • the neuromuscular disease is hyperhidrosis.
  • a subject suffering from hyperhidrosis receives about 59 U per axilla, or about 58 U per axilla, or about 57 U per axilla, or about 56 U per axilla, or about 55 U per axilla, or about 54 U per axilla, or about 53 U per axilla, or about 52 U per axilla, or about 51 U per axilla, or about 50 U per axilla, or about 49 U per axilla, or about 48 U per axilla, or about 47 U per axilla, or about 46 U per axilla, or about 45 U per axilla, or about 44 U per axilla, or about 43 U per axilla, or about 42 U per axilla, or about 41 U per axilla, or about 40 U per axilla, or about 39 U per axilla, or about 38 U per axilla, or about 37 U
  • the neuromuscular disease is hemifacial spasm.
  • a subject suffering from hemifacial spasm for example receives between about 1.5 to 15 U per treatment of the pharmaceutical formulation of the present invention.
  • the subject receives between about 1.5 to 3 U, 1.5 to 5 U, 1.5 to 7 U, 1.5 to 10 U, 1.5 to 12 U, 1.5 to 15 U, 5 to 10 U, 5 to 15 U, or 10 to 15 U per treatment are administered to a patient with hemifacial spasm.
  • the subject receives about 1.5 U, about 2 U, about 2.5 U, about 3 U, about 3.5 U, about 4 U, about 4.5 U about 5 U, about 5.5 U, about 6 U, about 6.5 U, about 7 U, about 7.5 U, about 8 U, about 8.5 U, about 9 U, about 9.5 U, about 10 U, about 10.5 U, about 11 U, about 11.5 U, about 12 U, about 12.5 U, about 13 U, about 13.5 U, about 14 U, about 14.5 U, or about 15 U per treatment are administered to a patient with hemifacial spasm. Dosages greater than 15 U per treatment may also be administered to patients with hemifacial spasm to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the neuromuscular disease is cervical dystonia.
  • a subject suffering from cervical dystonia receives between about 15 to 300 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 35 to 250 U, 65 to 200 U, 85 to 175 U, 105 to 160 U, or 125 to 145 U are administered to a patient with cervical dystonia.
  • dosages to the stemocleidomastoid muscle are limited to 100 U or less. Dosages greater than 300 U per treatment may also be administered to patients with cervical dystonia to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the neuromuscular disease is blepharospasm.
  • a subject suffering from blepharospasm receives between about 1.25 to 2.5 U of a pharmaceutical formulation of the present invention injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pretarsal orbicularis oculi of the lower lid.
  • the subject receives about 1.5 U, about 1.6 U, about 1.7 U, about 1.8 U, about 1.9 U, about 2.0 U, about 2.1 U, about 2.2 U, about 2.3 U, about 2.4 U, about 2.5 U, or more, per injection site.
  • a treatment session can comprise multiple treatments.
  • the neuromuscular disease is strabismus.
  • a subject suffering from strabismus receives between about 1.25 to 2.5 U per injection site of a pharmaceutical formulation of the present invention.
  • the subject recieves about 1.5 U, about 1.6 U, about 1.7 U, about 1.8 U, about 1.9 U, about 2.0 U, about 2.1 U, about 2.2 U, about 2.3 U, about 2.4 U, about 2.5 U, or more, per injection site to achieve a therapeutic response.
  • lower doses are used for treatment of small deviations.
  • vertical muscles and horizontal strabismus of less than 20 prism diameters can be treated with 1.25 to 2.5 U per injection site.
  • a treatment session can comprise multiple treatments.
  • the neuromuscular disease is muscle spasticity.
  • a subject suffering from muscle spasticity for example, receives between about 20 to 200 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 20 to 30 U, 20 to 40 U, 20 to 60 U, 20 to 80 U, 20 to 100 U, 20 to 125 U, 20 to 150 U, or 20 to 175 U per treatment are administered to a patient with muscle spasticity.
  • the subject receives about 20 U, about 25 U, about 30 U, about 35 U, about 40 U, about 45 U, about 50 U, about 55 U, about 60 U, about 65 U, about 70 U, about 75 U, about 80 U, about 85 U, about 90 U, about 95 U, about 100 U, about 105 U, about 110 U, about 115 U, about 120 U, about 125 U, about 130 U, about 135 U, about 140 U, about 145 U, about 150 U, about 155 U, about 160 U, about 165 U, about 170 U, about 175 U, about 180 U, about 185 U, about 190 U, about 195 U, or about 200 U per treatment are administered to a patient with muscle spasticity.
  • the biceps brachii can be injected with between 100 U and 200 U divided into 4 injection sites.
  • the flexor carpi radialis can be injected with between 12.5 U and 50 U in 1 injection site.
  • the flexor carpi ulnaris can be injected with between 12.5 U and 50 U in 1 injection site.
  • the flexor digitorum profundus can be injected with between 30 U and 50 U in one injection site.
  • the flexor digitorum sublimis can be injected with between 30 U and 50 in a single injection site. Dosages greater than 200 U per treatment may also be administered to patients with muscle spasticity to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the present invention provides methods for treating pain comprising the step of administering a pharmaceutical formulation of the present invention to a subject in need thereof in an amount sufficient to reduce pain.
  • the patient suffers from myofascial pain, migraine headache pain, tension headache pain, neuropathic pain, facial pain, lower-back pain, sinus-headache pain, pain associated with temporomandibular joint disease, pain associated with spasticity or cervical dystonia, post-surgical wound pain, or neuralgia.
  • a treatment session can comprise multiple treatments.
  • the patient suffers from facial pain.
  • a subject suffering from facial pain for example, receives between about 4 to 40 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 4 to 10 U, 4 to 15 U, 4 to 20 U, 4 to 25 U, 4 to 30 U, 4 to 35 U, 7 to 15 U, 7 to 20 U, 7 to 25 U, 7 to 30 U, 7 to 35 U, or 7 to 40 U per treatment are administered to a patient suffering from facial pain.
  • the subject receives about 4 U, about 5 U, about 7.5 U, about 10 U, about 12.5 U, about 15 U, about 17.5 U, about 20.0 U, about 22.5 U, about 25.0 U, about 27.5 U, about 30.0 U, about 32.5 U, about 35 U, about 37.5 U, or about 40 U per treatment are administered to a patient with facial pain. Dosages greater than 40 U per treatment may also be administered to patients with facial pain to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the patient suffers from myofascial pain.
  • a subject suffering from myofascial pain receives between about 5 to 100 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 5 to 10 U, 5 to 20 U, 5 to 30 U, 5 to 40 Units, 5 to 50 Units, 5 to 60 Units, 5 to 70 Units, 5 to 80 Units, 5 to 90 U, 10 to 20 U, 10 to 30 U, 10 to 50 U, or 10 to 60 U, or 10 to 70 U, or 10 to 80 U, 10 to 90 U, or 10 to 100 U per treatment are administered to a patient suffering from myofascial pain.
  • the subject receives about 5 U, about 10 U, about 15 U, about 20 U, about 25 U, about 30 U, about 35 U, about 40 U, about 45 U, about 50 U, about 55 U, about 60 U, about 65 U, about 70 U, about 75 U, about 80 U, about 85 U, about 90 U, about 95 U, or about 100 U per treatment are administered to a patient with myofascial pain. Dosages greater than 100 U per treatment may also be administered to patients with myofascial pain to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the subject suffers from lower-back pain.
  • a subject suffering from lower-back pain for example, receives between about 15 to 150 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 15 to 30 U, 15 to 50 U, 15 to 75 U, 15 to 100 U, 15 to 125 U, 15 to 150 U, 20 to 100 U, 20 to 150 U, or 100 to 150 U per treatment are administered to a patient with lower-back pain.
  • the subject receives about 15 U, about 20 U, about 25 U, about 30 U, about 35 U, about 40 U, about 45 U, about 50 U, about 55 U, about 60 U, about 65 U, about 70 U, about 75 U, about 80 U, about 85 U, about 90 U, about 95 U, about 100 U, about 105 U, about 110 U, about 115 U, about 120 U, about 125 U, about 130 U, about 135 U, about 140 U, about 145 U, or about 150 U per treatment are administered to a patient with lower-back pain. Dosages greater than 150 U per treatment may also be administered to patients with lower-back pain to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the patient suffers from migraine headache pain, including wherein the patient suffers from migraine headaches of 4 hours or more 15 or more days per month.
  • a subject suffering from migraine-headache pain for example, receives between about 0.5 to 200 U per treatment of a pharmaceutical formulation of the present invention. In a further example, the subject receives between about 5 to 190 U, 15 to 180 U, 25 to 170 U, 35 to 160 U, 45 to 150 U, 55 to 140 U, 65 to 130 U, 75 to 120 U, 85 to 110 U, or 95 to 105 U per treatment are administered to a patient suffering from migraine-headache pain.
  • a treatment session can comprise multiple treatments.
  • about 0.5 U, about 1.0 U, about 1.5 U, about 2.0 U, about 2.5 U, about 3.0 U, about 3.5 U, about 4.0 U, about 4.5 U, about 5.0 U, about 5.5 U, about 6.0 U, about 6.5 U, about 7.0 U, about 7.5 U, about 8.0 U, about 8.5 U, about 9.0 U, about 9.5 U, about 10.0 U, about 12 U, about 15 U, about 17 U, about 20 U, about 22 U, about 25 U, about 27 U, about 30 U, about 32 U, about 35 U, about 37 U, about 40 U, about 42 U, about 45 U, about 47 U, or about 50 U per treatment site are administered to a patient with migraine-headache pain.
  • a patient can be treated at multiple sites, such as, for example, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites, 18 sites, 19 sites, 20 sites, 21 sites, 22 sites, 23 sites, 24 sites, 25 sites, 26 sites, 27 sites, 28 sites, 29 sites, 30 sites, 31 sites, 32 sites, or more, or the like.
  • a patient suffering from migraine is injected 31 times with 5 U per 0.1 mL injection, across the corrugator (2 injections of 5 U each), procerus (1 injection of 5 U), frontalis (4 injections of 5 U each), temporalis (8 injections of 5 U each), occipitalis (6 injections of 5 U each), cervical paraspinal (4 injections of 5 U each), and trapezius (6 injections of 5 U each) muscles.
  • procerus muscle which can be injected at the midline, all muscles can, in certain embodiments, be injected bilaterally with half of the injection sites to the left and half to the right side of the head and neck. Dosages greater than 200 U per treatment may also be administered to patients with migraine-headache pain to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the patient suffers from sinus-headache pain.
  • a subject suffering from sinus-headache pain for example, receives between about 4 to 40 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 4 to 10 U, 4 to 15 U, 4 to 20 U, 4 to 25 U, 4 to 30 U, 4 to 35 U, 7 to 15 U, 7 to 20 U, 7 to 25 U, 7 to 30 U, 7 to 35 U, or 7 to 40 U per treatment are administered to a patient suffering from sinus-headache pain.
  • the subject receives about 4 U, about 5 U, about 7.5 U, about 10 U, about 12.5 U, about 15 U, about 17.5 U, about 20.0 U, about 22.5 U, about 25.0 U, about 27.5 U, about 30.0 U, about 32.5 U, about 35 U, about 37.5 U, or about 40 U per treatment are administered to a patient with sinus-headache pain. Dosages greater than 40 U per treatment may also be administered to patients with sinus headache-pain to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the patient suffers from tension-headache pain.
  • a subject suffering from tension-headache pain for example, receives between about 5 to 50 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 5 to 10 U, 5 to 15 U, 5 to 20 U, 5 to 25 U, 5 to 30 U, 5 to 35 U, 5 to 40 U, 5 to 45 U, 10 to 20 U, 10 to 25 U, 10 to 30 U, 10 to 35 U, 10 to 40 U, or 10 to 45 U per treatment are administered to a patient with tension-headache pain.
  • the subject receives about 5 U, about 10 U, about 20 U, about 25 U, about 30 U, about 35 U, about 40 U, about 45 U, or about 50 U per treatment are administered to a patient with tension-headache pain.
  • a patient suffering from tension headache is injected 31 times with 5 U per 0.1 mL injection, across the corrugator (2 injections of 5 U each), procerus (1 injection of 5 U), frontalis (4 injections of 5 U each), temporalis (8 injections of 5 U each), occipitalis (6 injections of 5 U each), cervical paraspinal (4 injections of 5 U each), and trapezius (6 injections of 5 U each) muscles.
  • all muscles can, in certain embodiments, be injected bilaterally with half of the injection sites to the left and half to the right side of the head and neck. Dosages greater than 200 U per treatment may also be administered to patients with tension headache pain to achieve a therapeutic response.
  • a treatment session can comprise multiple treatments.
  • the patient suffers from sinus headache pain or facial pain associated with acute or recurrent chronic sinusitis.
  • a pharmaceutical formulation of the present invention can be administered to the nasal mucosa or to the subcutaneous structures overlying the sinuses, wherein the administration of the formulation reduces the headache and/or facial pain associated with acute recurrent or chronic sinusitis.
  • any of the pharmaceutical formulations of the present invention can be administered to the nasal mucosa or to the subcutaneous structures overlying the sinuses, such as over one or more of the sinuses selected from the group consisting of: ethmoid; maxillary; mastoid; frontal; and sphenoid.
  • subcutaneous structures overlying the sinuses lie within one or more of the areas selected from the group consisting of: forehead; malar; temporal; post auricular; and lip.
  • multiple injections of 5 U each are administered to treat the sinus headache pain or facial pain associated with acute or recurrent chronic sinusitis.
  • a patient suffering from sinus headache pain or facial pain associated with acute or recurrent chronic sinusitis is treated by administering any of the pharmaceutical formulations of the present invention to an afflicted area of the patient.
  • the pharmaceutical formulations disclosed herein are administered to the projections of a trigeminal nerve innervating a sinus.
  • Patients suffering from sinus headache pain or facial pain associated with acute or recurrent chronic sinusitis often exhibit symptoms including rhinitis, sinus hypersecretion and/or purulent nasal discharge.
  • patients treated with the pharmaceutical formulations of the present invention exhibit symptoms of sinus hypersecretion and purulent nasal discharge.
  • Embodiments of the present invention also provide methods for treating a patient suffering from sinus headache pain or facial pain associated with acute or recurrent chronic sinusitis, wherein the subject suffers from neuralgia.
  • the neuralgia is trigeminal neuralgia.
  • the neuralgia is: associated with compressive forces on a sensory nerve; associated with intrinsic nerve damage, demyelinating disease, or a genetic disorder; associated with a metabolic disorder; associated with central neurologic vascular disease; or associated with trauma.
  • the pain is associated with dental extraction or reconstruction.
  • the invention also provide methods for treating a patient suffering from overactive bladder (OAB), such as, for example, that due to a neurologic condition (NOAB), or idiopathic OAB (IOAB).
  • OAB overactive bladder
  • NOAB neurologic condition
  • IOAB idiopathic OAB
  • pharmaceutical formulations of the present invention can be administered to the bladder or its vicinity, e.g. the detrusor, wherein the administration of the formulation reduces the urge incontinence associated with overactive bladder.
  • the dosage can be, for example, 200 U, or more, or less, or the like.
  • the dosage can be about 15 U, about 20 U, about 25 U, about 30 U, about 35 U, about 40 U, about 45 U, about 50 U, about 55 U, about 60 U, about 65 U, about 70 U, about 75 U, about 80 U, about 85 U, about 90 U, about 95 U, about 100 U, about 105 U, about 110 U, about 115 U, about 120 U, about 125 U, about 130 U, about 135 U, about 140 U, about 145 U, about 150 U, about 160 U, about 170 U, about 180 U, about 190 U, about 200 U, about 210 U, about 220, about 230 U, about 240 U, or more, or the like, per treatment.
  • a patient can be injected at multiple sites, such as, for example, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites, 18 sites, 19 sites, 20 sites, 21 sites, 22 sites, 23 sites, 24 sites, 25 sites, 26 sites, 27 sites, 28 sites, 29 sites, 30 sites, 31 sites, 32 sites, 33 sites, 34 sites, 35 sites, 36 sites, 37 sites, 38 sites, or more, or the like.
  • patients suffering from OAB are treated with 30 1 mL injections of approximately 6.7 U per injection into the detrusor muscle.
  • the invention also provides methods for treating a patient suffering from neurogenic detrusor overactivity (NDO), such as that due to a neurologic condition.
  • NDO neurogenic detrusor overactivity
  • pharmaceutical formulations of the present invention can be administered to the bladder or its vicinity, e.g. the detrusor, wherein the administration of the formulation reduces the urge incontinence associated with overactive bladder.
  • the dosage can be, for example, 200 U, or more, or less, or the like.
  • the dosage can be about 15 U, about 20 U, about 25 U, about 30 U, about 35 U, about 40 U, about 45 U, about 50 U, about 55 U, about 60 U, about 65 U, about 70 U, about 75 U, about 80 U, about 85 U, about 90 U, about 95 U, about 100 U, about 105 U, about 110 U, about 115 U, about 120 U, about 125 U, about 130 U, about 135 U, about 140 U, about 145 U, about 150 U, about 160 U, about 170 U, about 180 U, about 190 U, about 200 U, about 210 U, about 220, about 230 U, about 240 U, or more, or the like, per treatment.
  • a patient can be injected at multiple sites, such as, for example, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites, 18 sites, 19 sites, 20 sites, 21 sites, 22 sites, 23 sites, 24 sites, 25 sites, 26 sites, 27 sites, 28 sites, 29 sites, 30 sites, 31 sites, 32 sites, or more, or the like.
  • patients suffering from NDO are treated with 30 1 mL injections of approximately 6.7 U per injection into the detrusor muscle.
  • the present invention provides methods for cosmetically modifying soft-tissue features comprising the step of administering at least one pharmaceutical formulation of the present invention to a subject in need thereof in an amount sufficient to modify said features.
  • the pharmaceutical formulation is administered via transcutaneous or transmucosal injection either at a single focus or multiple foci.
  • pharmaceutical formulations of the present invention are administered to the face or neck of the subject.
  • the pharmaceutical formulations of the present invention are administered to the subject in an amount sufficient to reduce rhytides.
  • the formulation can be administered between eyebrows of the subject in an amount sufficient to reduce vertical lines between the eyebrows and on a bridge of a nose.
  • the pharmaceutical formulations can also be administered near either one or both eyes of the subject in an amount sufficient to reduce lines at corners of the eyes.
  • compositions of the invention can be injected locally to smooth skin.
  • the pharmaceutical formulations of the present invention can also be administered to a forehead of the subject in an amount sufficient to reduce horizontal lines on said forehead.
  • the pharmaceutical formulation is administered to the neck of the subject in an amount sufficient to reduce muscle bands in the neck.
  • a pharmaceutical composition is applied to the masseter muscle to relax the muscle and/or decrease masseter mass.
  • the patient suffers from facial wrinkles.
  • a subject suffering from facial wrinkles can receive between about 1 to 100 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 1 to 10 U, 1 to 20 U, 1 to 30 U, 1 to 40 U, 1 to 50 U, 1 to 60 U, 1 to 70 U, 1 to 80 U, 1 to 90 U, 5 to 20 U, 5 to 30 U, 5 to 40 U, 5 to 50 U, 5 to 60 U, 5 to 70 U, 5 to 80 U, 5 to 90 U, or 5 to 100 U per treatment are administered to a patient with an inflammatory disorder.
  • about 1 U, about 10 U, about 20 U, about 30 U, about 40 U, about 50 U, about 60 U, about 70 U, about 80 U, about 90 U, or about 100 U per treatment are administered to a patient. Dosages greater than 100 U per treatment may also be administered to patients suffering from inflammation or an inflammatory disorder to achieve a therapeutic response.
  • the present invention provides methods for treating inflammation comprising the step of administering a pharmaceutical formulation of the present invention to a subject in need thereof in an amount sufficient to reduce inflammation.
  • pharmaceutical formulations of the present invention are administered to a patient without producing muscle weakness.
  • the pharmaceutical formulations of the present invention are administered to patients with an inflammatory condition.
  • the inflammatory condition is neurogenic inflammation.
  • the subject suffers from rheumatoid arthritis or a gastro-intestinal inflammatory disease.
  • the patient suffers from an inflammatory disorder.
  • a subject suffering from an inflammatory disorder for example, receives between about 1 to 100 U per treatment of a pharmaceutical formulation of the present invention.
  • the subject receives between about 1 to 10 U, 1 to 20 U, 1 to 30 U, 1 to 40 U, 1 to 50 U, 1 to 60 U, 1 to 70 U, 1 to 80 U, 1 to 90 U, 5 to 20 U, 5 to 30 U, 5 to 40 U, 5 to 50 U, 5 to 60 U, 5 to 70 U, 5 to 80 U, 5 to 90 U, or 5 to 100 U per treatment are administered to a patient with an inflammatory disorder.
  • about 1 U, about 10 U, about 20 U, about 30 U, about 40 U, about 50 U, about 60 U, about 70 U, about 80 U, about 90 U, or about 100 U per treatment are administered to a patient. Dosages greater than 100 U per treatment may also be administered to patients suffering from inflammation or an inflammatory disorder to achieve a therapeutic response.
  • a method within the scope of the present invention for treating a skin disorder can have the step of local administration of a botulinum neurotoxin to a location of a skin disorder of a patient, such as to a face, hand or foot of a patient.
  • the neurotoxin can be locally administered in an amount of between about 10-3 units/kg of patient weight and about 35 units/kg of patient weight.
  • the neurotoxin is locally administered in an amount of between about 10-2 U/kg and about 25 U/kg of patient weight.
  • the neurotoxin is administered in an amount of between about 10-1 U/kg and about 15 U/kg.
  • the neurotoxin is locally administered in an amount of between about 1 U/kg and about 10 U/kg.
  • a neurotoxin such as botulinum toxin type A or B
  • a skin disorder location by topical application or by subdermal administration, to effectively treat the skin disorder.
  • Administration of botulinum toxin can be carried out at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.1 to 10 cm, or about 0.5 to about 5 cm, for example, by about 1.5 to about 3 cm.
  • the toxins may be any of the botulinum toxins A, B, C, D, E, F or G.
  • the amounts administered may vary between 0.1 and 1000 U, or about 1 to about 40, or from about 5 to about 10 U, depending on the manufactures specifications, the class of the toxin and the mode of administration.
  • the repeat time range for these administrations for maintenance of the desired change varies substantially according to the location of the injection, the condition to be adjusted and the condition of the patient. Thus the repeat time may vary from about 1 week to about 50 weeks, however a common range is about 4 to about 25 weeks, or even about 12 weeks to about 16 weeks.
  • the distances between administrations can vary from about 1 mm to about 10 cm, suitably from about 5 mm to about 5 cm, and more usually from about 1 cm to about 3 cm.
  • botulinum A may be suitably administered by intradermal injection between about 0.1 to about 10 U at a separation of from about 0.5 to about 10 cm.
  • the present invention provides methods for treating cutaneous disorders comprising the step of administering a pharmaceutical formulation of the present invention to a subject in need thereof in an amount sufficient to reduce a sebaceous or mucous secretion.
  • the pharmaceutical formulations of the present invention are administered to a patient without producing muscle weakness.
  • the pharmaceutical formulations of the present invention are injected into one or more sites of an eyelid or conjunctiva.
  • the formulations of the present invention are administered to a body surface.
  • the pharmaceutical formulations are administered in an amount sufficient to reduce cutaneous bacterial or fungal growth, including but not limited to Staphylococcus; Streptococcus and Moraxella .
  • the pharmaceutical formulations of the present invention are administered to an area selected from the group consisting of: eyelid; scalp; feet; groin; and armpit to reduce cutaneous infection.
  • Bulk drug product solutions were prepared by mixing an appropriate aliquot of a botulinum toxin type A with three different vehicle solutions as shown in Table 4. All three formulations contained 8% w/w trehalose, 4% w/w P188 and 20 mM Histidine buffer at pH 6.0. The target potency was 100 units/mL. Formulation 10 contained no antioxidant. Formulations 11 and 12 contained NAC and methionine, respectively. The bulk solutions were filled into 2 mL glass vials (1.25 mL fill), and sealed with rubber stopper and aluminum shell.
  • N-acetyl-L-cysteine accelerated loss of potency as compared with the antioxidant-free formulation, demonstrating that N-acetyl-L-cysteine acted as pro-oxidant in this formulation.
  • the liquid composition comprising NAC lost over 50% potency after storage for 1 month at 25° C. and lost essentially all activity (i.e., complete inactivation of the toxin) after storage for 1 month at 40° C.
  • the lyophilized compositions comprising NAC lost 7% ((98.6%-91.9%)/98.6%) potency after storage for 3 months at 25° C. and lost 12% ((98.6%-86.5%)/98.6%) potency after storage for 1 month at 40° C. This demonstrates that NAC can function as a stabilizer in the lyophilized compositions.
  • Bulk drug product solutions were prepared by mixing an appropriate aliquot of a botulinum toxin type A with different antioxidants as shown in Table 5. All formulations contained 8% w/w trehalose, 4% w/w P188, 20 mM Histidine buffer at pH 6.0 and one or more antioxidants as listed. Target potency was 100 U/mL. The bulk solutions were filled into 2 mL glass vials (1.25 mL fill), and sealed with rubber stopper and aluminum shell. Potency of the formulations was tested by a cell based potency assay (CBPA) after filling (time zero, t0) and storage for two weeks and 1 month at 40° C. Potency test results are given in Table 5.
  • CBPA cell based potency assay
  • Liquid compositions comprising NAC and EDTA sodium salt retained full potency after storage at 40° C. for 2 weeks and 1 month, as did a composition comprising NAC, EDTA sodium salt and tryptophan (Formulation 27).
  • a composition comprising NAC but not EDTA lost essentially all potency after 2 weeks storage at 40° C.
  • antioxidants a chelating agent (e.g., EDTA, EGTA or DTPA) and/or a chain terminator antioxidant (e.g., methionine, cysteine, NAC and BHT) provides a stabilizing effect on the botulinum toxin.
  • Each formulation contained 100 U/mL botulinum toxin, 8 w/w % trehalose, and 4 w/w % poloxamer P188 in 20 mM histidine buffer, pH 6.0 and the specified antioxidant.
  • NAC N-acetyl-L-cysteine
  • Met L-methionine
  • TRP L-tryptophan
  • GSH L-glutathione
  • NaSul sodium sulfite
  • PrpGal propyl gallate
  • Bulk drug product solutions were prepared by mixing an appropriate aliquot of a botulinum toxin type A with a poloxamer or a polysorbate as shown in Table 6. All formulations contained 8% w/w trehalose, 0.2% w/w methionine in 20 mM Histidine buffer at pH 6.0 and 4% w/w P188 or 0.04% w/w Tween-20 as listed. Target potency was 100 U/mL. The bulk solutions were filled into 2 mL glass vials (1.25 mL fill), and sealed with rubber stopper and aluminum shell. Potency of the formulations was tested by a cell based potency assay (CBPA) after filling to give an initial potency.
  • CBPA cell based potency assay
  • Bulk drug product solutions were prepared by mixing an appropriate aliquot of a botulinum toxin type A with different components as shown in Tables 7 and 8. The amounts of components contained were 0% or 8% w/w trehalose, 0% or 0.2% w/w methionine, 0% or 4% w/w P188, all of which were formulated in 20 mM Histidine buffer at pH 6.0. Target potency was 100, 150, or 200 U/mL. The bulk solutions were filled into 2 mL glass vials (1.25 mL fill), and sealed with rubber stopper and aluminum shell. Potency of the formulations was tested by a cell based potency assay (CBPA) after filling to give an initial potency.
  • CBPA cell based potency assay
  • Bulk drug product solutions were prepared by mixing an appropriate aliquot of a botulinum toxin type A with vehicle solutions, containing different stabilizers and surfactants as shown in Table 9. All formulations contained 8% or 0% w/w trehalose or sucrose, 4% w/w P188 or 0.04% w/w PS-20, optionally 20 mM Histidine buffer at pH 6.0, 0.2% w/w methionine, and optionally 0.9% w/w NaCl. Target potency was 100 U/mL. The bulk solutions were filled into 2 mL glass vials (1.25 mL fill), and sealed with rubber stopper and aluminum shell. Potency of the formulations was tested by cell based potency assay (CBPA) after filling (time zero, t0) and storage at 5° C. Potency test results are given in Table 10.
  • CBPA cell based potency assay
  • Bulk solutions of botulinum toxin were prepared by mixing an appropriate aliquot of a botulinum toxin type A with several vehicle solutions as described in Table 11.
  • the amounts of components contained were 0% or 8% w/w trehalose or sucrose, 0.2% w/w methionine, 0% or 4% w/w P188, 0% or 0.04% w/w Tween 20 all of which were formulated in 20 mM Histidine buffer at pH 6.0.
  • Target potency was 200 U/mL. These amounts are shown in Table 11 below.
  • the solutions were filled into glass vials and lyophilized using conventional freeze-drying conditions.
  • a 58-year-old college professor presents symptoms of depression.
  • Her physician diagnoses recurrent moderate to severe major depressive disorder (MDD) based upon the DSM-IV-TR criteria.
  • the physician administers by intramuscular injection a botulinum toxin solution made using the composition shown in Table A reconstituted in saline into the procerus and corrugator muscles in a single treatment session. 30 units in total are administered at 6 injection sites. The procerus and corrugator muscles are paralysed. It is later confirmed using the Montgomery-Asberg Depression Rating scale that the treatment has alleviated the depression. Additional efficacy measures including the clinic CGI-S score (Clinical Global Impression of Change scores), and the clinic HAM-D17 total score (Hamilton Rating Scale for Depression) further confirm this. The treatment is repeated after 3 months.
  • MDD major depressive disorder
  • a 41-year-old teacher undergoing cardiac surgery shows symptoms of cardiac arrhythmia.
  • the surgeon administers a botulinum toxin solution made using the composition shown in Table A reconstituted in saline into the major epicardial fat pads of the heart of the patient. 50 U is administered per epicardial fat pad, up to a total of 250 U.
  • the patient is followed by ECG for a four week period following the injection. The incidence of atrial fibrillation is reduced.
  • the following improvements are noted for this patient: the length of hospital stay is reduced, length of stay in ICU is reduced, anticoagulant medication use is reduced, and the need for interventional procedures for Post Operative Atrial fibrillation (POAF) such as ablation, pacemaker implantation, electrical or pharmacologic cardioversion are reduced.
  • POAF Post Operative Atrial fibrillation
  • Example 12 Treatment of Cardiac Arrhythmia with Exemplary Compositions
  • a 66-year-old pensioner undergoing cardiac surgery shows symptoms of cardiac arrhythmia.
  • the surgeon administers a botulinum toxin solution made using the composition shown in Table A reconstituted in saline into the major epicardial fat pads of the heart of the patient. 25 U is administered per epicardial fat pad, up to a total of 125 U.
  • the patient is followed by ECG for a four week period following the injection. The incidence of atrial fibrillation is reduced.
  • the length of hospital stay is reduced, length of stay in ICU is reduced, anticoagulant medication use is reduced, and the need for interventional procedures for Post Operative Atrial fibrillation (POAF) such as ablation, pacemaker implantation, electrical or pharmacologic cardioversion are reduced.
  • POAF Post Operative Atrial fibrillation
  • the present disclosure also includes the following set of articles:
  • a pharmaceutical composition comprising:
  • composition according to article 1 comprising botulinum toxin. 3.
  • the composition according to article 1 or article 2 comprising trehalose. 4.
  • the composition according to any one of articles 1 to 3, comprising poloxamer 188 and/or polysorbate 20. 5.
  • the composition according to any one of articles 1 to 4 comprising one or more of methionine and N-Acetyl-cysteine.
  • the composition according to any one of articles 1 to 5 comprising botulinum toxin, trehalose, one of poloxamer 188 or polysorbate 20, and one of methionine or N-Acetyl-cysteine. 7.
  • composition according to any one of articles 1 to 6, comprising botulinum toxin, trehalose, poloxamer 188, and methionine.
  • composition according to article 7 wherein the relative weight amounts (%, w/w) of trehalose, poloxamer 188, and methionine are within the following ranges:
  • trehalose 1 to 10 polysorbate 20 0.02 to 0.06 methionine 0.1 to 0.3 11.
  • trehalose 1 to 10 poloxamer 188 0.5 to 5 N-Acetyl-cysteine 0.01 to 0.5 13.
  • trehalose 1 to 10 polysorbate 20 0.02 to 0.06 N-Acetyl-cysteine 0.01 to 0.5 15.
  • the present disclosure also includes the following set of embodiments.
  • a pharmaceutical composition comprising:
  • composition according to embodiment 1 comprising botulinum toxin. 3.
  • the composition according to embodiment 1 or embodiment 2 comprising trehalose or sucrose. 4.
  • the composition according to any one of embodiments 1 to 3, comprising poloxamer 188 and/or polysorbate 20. 5.
  • the composition according to any one of embodiments 1 to 4 comprising one or more of methionine and N-Acetyl-cysteine. 6.
  • the composition according to any one of embodiments 1 to 5 comprising botulinum toxin, trehalose or sucrose, one of poloxamer 188 or polysorbate 20, and one of methionine or N-Acetyl-cysteine. 7.
  • composition according to any one of embodiments 1 to 6, comprising botulinum toxin, trehalose or sucrose, poloxamer 188, and methionine.
  • composition according to embodiment 8 wherein the relative weight amounts (%, w/w) of trehalose or sucrose, poloxamer 188, and methionine are:
  • composition according to any one of embodiments 7-9, wherein the composition is a liquid composition, wherein the composition preferably comprises a buffer.
  • the buffer is histidine, wherein the concentration of histidine is preferably 20 mM, wherein the pH is preferably in the range 5-7, and wherein the pH is more preferably in the range 5.5-6.5, and the pH is most preferably in the range 5.5-6. 12.
  • composition according to embodiment 10 wherein the composition consists of trehalose or sucrose, poloxamer 188, methionine, a buffer, and optionally NaCl, and optionally EDTA, wherein the buffer is preferably histidine, wherein the pH is preferably in the range 5-7, the pH is more preferably in the range 5.5-6.5, and wherein the pH is most preferably in the range 5.5-6. 13.
  • composition according to embodiment 13 further comprising a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).
  • the composition according to embodiment 13 or 14 wherein the composition consists of trehalose or sucrose, poloxamer 188, methionine, a buffer, and optionally NaCl, and optionally EDTA.
  • the relative weight amounts (%, w/w) of trehalose or sucrose, polysorbate 20, and methionine are within the following ranges:
  • trehalose or sucrose 1 to 10 polysorbate 20 0.02 to 0.06 methionine 0.1 to 0.3 18.
  • the composition according to embodiment 18, wherein the relative weight amounts (%, w/w) of trehalose or sucrose, poloxamer 188, and N-Acetyl-cysteine are within the following ranges:
  • composition according to embodiment 19 wherein the relative weight amounts (%, w/w) of trehalose or sucrose, poloxamer 188, N-Acetyl-cysteine, and EDTA are:
  • compositions according to any one of embodiments 18-21, wherein the composition is a solid composition, wherein the composition is preferably lyophilised.
  • the composition is a liquid composition, wherein the composition preferably comprises a buffer.
  • the buffer is histidine, wherein the concentration of histidine is preferably 20 mM, wherein the pH is preferably in the range 5-7, and wherein the pH is most preferably 6.
  • composition according to embodiment 25 wherein the composition consists of trehalose or sucrose, poloxamer 188, N-Acetyl-cysteine, a buffer, and optionally EDTA, wherein the buffer is preferably histidine, wherein the pH is preferably in the range 5-7, and wherein the pH is most preferably 6.
  • the composition according to embodiment 28, wherein the relative weight amounts (%, w/w) of trehalose or sucrose, polysorbate 20, and N-Acetyl-cysteine are within the following ranges:
  • a pharmaceutical composition comprising:
  • composition according to embodiment 30 comprising botulinum toxin.
  • the composition according to embodiment 30 or 31, comprising poloxamer 188 and/or polysorbate 20.
  • the composition according to any one of embodiments 30 to 32 comprising one or more of methionine and N-Acetyl-cysteine.
  • the composition according to any one of embodiments 30 to 33 comprising botulinum toxin, one of poloxamer 188 or polysorbate 20, and one of methionine or N-Acetyl-cysteine.
  • the composition according to any one of embodiments 30 to 34 comprising botulinum toxin, poloxamer 188, and methionine.
  • the composition according to embodiment 35 wherein the relative weight amounts (%, w/w) of poloxamer 188, and methionine are within the following ranges:
  • poloxamer 188 0.5 to 5 methionine 0.1 to 0.3.
  • the composition is a liquid composition, wherein the composition preferably comprises a buffer.
  • the buffer is histidine, wherein the concentration of histidine is preferably 20 mM, wherein the pH is preferably in the range 5-7, and wherein the pH is most preferably 6. 40.
  • composition according to embodiment 38 wherein the composition consists of poloxamer 188, methionine, and a buffer, wherein the buffer is preferably histidine, wherein the pH is preferably in the range 5-7, and wherein the pH is most preferably 6.
  • the composition according to any one of embodiments 1 to 10, 12 to 25, 27 to 38, or 40 comprising histidine.
  • the composition according to any previous claim comprising no animal-derived protein.
  • 43. comprising ethylene diamine tetraacetic acid sodium salt (EDTA) or an EDTA analog.
  • EDTA ethylene diamine tetraacetic acid sodium salt
  • 44 The composition according to embodiment 43, wherein the relative weight amount (%, w/w) of EDTA ranges from about 0.01 to 0.10. 45.
  • composition according to any one of embodiments 18, 19, 28, 29, 43 and 44, wherein the composition is a liquid formulation and has a pH of from 5 to 7, wherein the relative weight amount of N-Acetyl-cysteine is 0.1 to 0.5.
  • the diseases, disorders, and conditions are selected from neuromuscular diseases, pain, psychological disorders, urological disorders, inflammation, and skin disorders.
  • 51. The method of embodiment 49, wherein the disorder is depression.
  • the method of embodiment 49, wherein the condition is cardiac arrhythmia.
  • a method of cosmetic treatment comprising the step of administering the pharmaceutical composition of any of embodiments 1 to 48 to a subject in need thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US16/332,923 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions Abandoned US20190247476A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/332,923 US20190247476A1 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394009P 2016-09-13 2016-09-13
PCT/US2017/051369 WO2018053004A2 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions
US16/332,923 US20190247476A1 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/051369 A-371-Of-International WO2018053004A2 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US202117230537A Continuation 2016-09-13 2021-04-14

Publications (1)

Publication Number Publication Date
US20190247476A1 true US20190247476A1 (en) 2019-08-15

Family

ID=59974865

Family Applications (8)

Application Number Title Priority Date Filing Date
US16/332,923 Abandoned US20190247476A1 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions
US15/703,527 Active US10369190B2 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions
US16/531,800 Active US10973890B2 (en) 2016-09-13 2019-08-05 Non-protein clostridial toxin compositions
US17/185,312 Abandoned US20210290739A1 (en) 2016-09-13 2021-02-25 Non-protein clostridial toxin compositions
US17/322,195 Abandoned US20210369821A1 (en) 2016-09-13 2021-05-17 Non-protein clostridial toxin compositions
US17/856,121 Abandoned US20230173041A1 (en) 2016-09-13 2022-07-01 Non-protein clostridial toxin compositions
US18/136,090 Pending US20230355724A1 (en) 2016-09-13 2023-04-18 Non-protein clostridial toxin compositions
US18/136,048 Pending US20230355723A1 (en) 2016-09-13 2023-04-18 Non-protein clostridial toxin compositions

Family Applications After (7)

Application Number Title Priority Date Filing Date
US15/703,527 Active US10369190B2 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions
US16/531,800 Active US10973890B2 (en) 2016-09-13 2019-08-05 Non-protein clostridial toxin compositions
US17/185,312 Abandoned US20210290739A1 (en) 2016-09-13 2021-02-25 Non-protein clostridial toxin compositions
US17/322,195 Abandoned US20210369821A1 (en) 2016-09-13 2021-05-17 Non-protein clostridial toxin compositions
US17/856,121 Abandoned US20230173041A1 (en) 2016-09-13 2022-07-01 Non-protein clostridial toxin compositions
US18/136,090 Pending US20230355724A1 (en) 2016-09-13 2023-04-18 Non-protein clostridial toxin compositions
US18/136,048 Pending US20230355723A1 (en) 2016-09-13 2023-04-18 Non-protein clostridial toxin compositions

Country Status (27)

Country Link
US (8) US20190247476A1 (ko)
EP (4) EP3436054B2 (ko)
JP (3) JP7217700B2 (ko)
KR (5) KR102480965B1 (ko)
CN (3) CN109803672A (ko)
AU (3) AU2017327369A1 (ko)
BR (2) BR112019004929A2 (ko)
CA (2) CA3036095A1 (ko)
CL (1) CL2019000586A1 (ko)
CO (1) CO2019003630A2 (ko)
CY (2) CY1122263T1 (ko)
DK (2) DK3432916T3 (ko)
ES (2) ES2755815T3 (ko)
HR (1) HRP20191966T4 (ko)
HU (2) HUE046449T2 (ko)
IL (2) IL308091A (ko)
LT (1) LT3436054T (ko)
MX (2) MX2019002835A (ko)
PH (1) PH12019500501A1 (ko)
PL (2) PL3436054T5 (ko)
PT (2) PT3432916T (ko)
RS (1) RS59600B2 (ko)
RU (2) RU2762607C2 (ko)
SA (1) SA519401298B1 (ko)
SI (2) SI3432916T1 (ko)
TW (2) TW202247855A (ko)
WO (2) WO2018053004A2 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973890B2 (en) 2016-09-13 2021-04-13 Allergan, Inc. Non-protein clostridial toxin compositions
US11033625B2 (en) * 2005-10-06 2021-06-15 Allergan, Inc. Method for stabilizing a toxin

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
CN112888454A (zh) * 2018-09-13 2021-06-01 阿勒根公司 梭菌毒素-透明质酸组合物
KR102259423B1 (ko) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
UY38744A (es) * 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
WO2021231669A1 (en) * 2020-05-15 2021-11-18 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
CA3154363C (en) 2019-10-18 2024-03-05 Penland Foundation Use of a botulinum toxin for treating autism and/or tolerance to narcotics
US10960060B1 (en) * 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
RU2746035C1 (ru) * 2020-06-30 2021-04-06 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ купирования болевого синдрома после эндопротезирования молочных желез
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin

Family Cites Families (441)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682047D1 (de) 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4958257A (en) 1989-03-29 1990-09-18 Hughes Aircraft Company Heat conducting interface for electronic module
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
CA2131709C (en) * 1992-03-13 2004-11-23 Terry R. Beardsley Immune-enhancing agent for therapeutic use in immunocompromised hosts
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
ATE292977T1 (de) 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
AU695623B2 (en) 1994-05-31 1998-08-20 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5556771A (en) 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DK0773788T3 (da) 1995-06-06 2003-09-01 Allergan Inc Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
ES2385130T3 (es) 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
SE510813C2 (sv) 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20050147690A1 (en) 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
ATE216223T1 (de) 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6573244B1 (en) 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
ES2277854T5 (es) 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
DE60043708D1 (de) 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20030138460A1 (en) 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
PT1253932E (pt) 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US6630330B1 (en) 2000-08-02 2003-10-07 Biopolo S.C.A.R.L. Ascorbic acid production from yeast
WO2002036110A2 (en) 2000-10-31 2002-05-10 Boehringer Ingelheim Pharmaceuticals, Inc. Oral self-emulsifying formulations of pyranone protease inhibitors
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US20060134140A1 (en) 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US9157875B2 (en) 2001-05-16 2015-10-13 Benjamin P. Warner Drug development and manufacturing
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US7491403B2 (en) 2002-12-20 2009-02-17 Botulinum Toxin Research Associates Pharmaceutical botulinum toxin compositions
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
AU2003287105A1 (en) 2002-10-10 2004-05-04 Verenium Corporation Proteases, nucleic acids encoding them and methods for making and using them
WO2004037225A2 (en) 2002-10-25 2004-05-06 Foamix Ltd. Cosmetic and pharmaceutical foam
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
AU2003287640A1 (en) 2002-11-12 2004-06-03 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20060074014A1 (en) 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060002862A1 (en) 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
ES2314362T3 (es) 2003-01-16 2009-03-16 Acadia Pharmaceuticals Inc. Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas.
WO2004076634A2 (en) 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
DE602004024041D1 (de) 2003-03-05 2009-12-24 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2004093870A1 (en) 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
JP5503837B2 (ja) 2003-03-26 2014-05-28 ポール，サッドヒル 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
US7341843B2 (en) 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7396535B2 (en) 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
UY28398A1 (es) 2003-07-02 2004-11-08 Alza Corp Método y parche de inmunización por disposición de microproyección
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050042775A1 (en) 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods
WO2005034852A2 (en) 2003-08-26 2005-04-21 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
EP1680178A4 (en) 2003-10-31 2008-01-02 Alza Corp SYSTEM AND METHOD FOR THE TRANSDERMAL DISTRIBUTION OF A VACCINE
WO2005051455A2 (en) 2003-11-21 2005-06-09 Alza Corporation Ultrasound assisted transdermal vaccine delivery method and system
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US8529939B2 (en) 2003-12-08 2013-09-10 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
CA2547343C (en) 2003-12-23 2013-05-14 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
KR20060134050A (ko) 2004-01-09 2006-12-27 알자 코포레이션 주파수 보조 경피성 약제 전달 방법 및 시스템
FR2865131B1 (fr) 2004-01-15 2007-08-24 Gattefosse Ets Sa Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides
US7598027B2 (en) 2004-02-24 2009-10-06 Allergan, Inc. Botulinum toxin screening assays
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US7674454B2 (en) 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
US20050220854A1 (en) 2004-04-01 2005-10-06 Yuh-Fun Maa Apparatus and method for transdermal delivery of influenza vaccine
WO2005098009A2 (en) 2004-04-09 2005-10-20 Wyeth Synergistic attenutation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
CA2562642A1 (en) 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
US7875436B2 (en) 2004-05-05 2011-01-25 Pharmaleads Peptide substrates recognizable by a botulinum toxin A, BoNT/A and the use thereof
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
AU2005242409A1 (en) 2004-05-19 2005-11-24 Alza Corporation Method and formulation for transdermal delivery of immunologically active agents
DE102004026152A1 (de) 2004-05-28 2005-12-15 Basf Ag Fermentative Herstellung von Feinchemikalien
WO2005123120A1 (en) 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
CN101001613B (zh) 2004-06-28 2010-09-29 生命周期药物公司 作为液体制剂载体的多孔片剂
US7825233B2 (en) 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
CA2799413A1 (en) 2004-07-26 2006-02-23 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
PL1776137T3 (pl) 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
GB2419527A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
JP2008508886A (ja) 2004-08-04 2008-03-27 アラーガン、インコーポレイテッド 活性ボツリヌス毒素ａ型の発現の最適化
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
EP1797109B1 (en) 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060057165A1 (en) 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
WO2006042149A2 (en) 2004-10-06 2006-04-20 Allergan, Inc. Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
US7205018B2 (en) 2004-10-07 2007-04-17 Next Proteins, Inc. Carbonated protein drink and method of making
EP1817043A4 (en) 2004-11-02 2010-01-27 Chr Hansen As CAPSULE BACTERIOPHAGE FORMULATION
WO2007001451A2 (en) 2004-11-09 2007-01-04 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
WO2006059093A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
WO2006073410A1 (en) 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
BRPI0508299A (pt) 2005-03-03 2007-07-31 Allergan Inc sistema livre de produto animal e processo para purificação de uma toxina botulina
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
CA2601577A1 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1870455A4 (en) 2005-03-31 2010-01-20 Two Cells Co Ltd METHOD FOR DISTINCTION OF MESENCHYMAL STEM CELL USING MOLECULAR MARKER AND USE THEREOF
EP2293064B1 (en) 2005-04-05 2012-04-04 Allergan, Inc. Lipophilic dye-based FRET assays for clostridial toxin activity
US20070029252A1 (en) 2005-04-12 2007-02-08 Dunson James B Jr System and process for biomass treatment
WO2006122123A2 (en) 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
HUE031380T2 (en) 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
CA2618974C (en) 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
PT1954308E (pt) 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CN101175478A (zh) * 2005-10-06 2008-05-07 阿勒根公司 非蛋白稳定的梭菌毒素药物组合物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2013202329B2 (en) * 2005-10-06 2016-04-14 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US20090324647A1 (en) 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US8158360B2 (en) 2005-12-08 2012-04-17 Novartis Ag Effects of inhibitors of FGFR3 on gene transcription
DK3326681T3 (da) 2005-12-30 2019-09-30 Rdd Pharma Ltd Indretning til behandling af analsphincteren
CA2637027A1 (en) 2006-01-10 2007-07-19 Ruey J. Yu N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
JP5457680B2 (ja) 2006-01-24 2014-04-02 アンサン バイオファーマ，インコーポレイテッド 高分子マイクロスフェアの調製技術
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
EP2105500A1 (de) 2008-03-26 2009-09-30 Pharmazell GmbH Neue 12alpha-Hydroxysteroiddehydrogenasen, deren Herstellung und deren Verwendung
US7473559B2 (en) 2006-04-05 2009-01-06 Charles Lee Method for measuring the content of a botulinum toxin in a formulation
US7309602B2 (en) 2006-04-13 2007-12-18 Ambrozea, Inc. Compositions and methods for producing fermentation products and residuals
ITTO20060282A1 (it) 2006-04-14 2007-10-15 Univ Degli Studi Torino Mezzo di coltura e composizione farmaceutica per la rigenerazione del tessuto cartilagineo relativo procedimento relativi usi e prodotti
JP2009543556A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US9061025B2 (en) 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8043845B2 (en) 2006-09-20 2011-10-25 American Sterilizer Company Sterilization indicator
DK2084519T3 (da) 2006-10-10 2012-08-20 Los Alamos Nat Security Llc Røntgenfluorescens-analysefremgangsmåde
EP1917971A1 (en) 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
DK2829282T3 (en) 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
EP1985276A1 (en) 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CA2690773C (en) 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
SI2198007T1 (en) 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
US8486467B1 (en) 2007-09-20 2013-07-16 Albert G. Prescott Dermal filler and method of using same
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
JP2011505148A (ja) 2007-11-30 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 商業的に価値のある化合物を産生するための生物学的システム
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SG10201604258YA (en) 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
KR20110007088A (ko) 2008-01-25 2011-01-21 비 앤드 티 에스.알.엘. 화장품 분야에서의 트랜스에스테르화 올리브 오일의 용도
KR101483715B1 (ko) 2008-01-31 2015-01-19 큐어백 게엠바하 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
US9233080B2 (en) 2008-03-27 2016-01-12 Agigma, Inc. Compositions and methods for the delivery of agents
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
WO2009128644A2 (ko) 2008-04-14 2009-10-22 한국과학기술원 게놈 수준에서의 부탄올 생산 미생물의 대사 네트워크 모델 및 이를 이용한 부탄올 생성 미생물의 대사특성분석 및 결실 표적 스크리닝 방법
RU2015127761A (ru) 2008-04-30 2015-10-20 Ксилеко, Инк. Переработка биомассы
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
WO2010011597A2 (en) 2008-07-22 2010-01-28 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP2998402A1 (en) 2008-10-17 2016-03-23 Joule Unlimited Technologies, Inc. Ethanol production by microorganisms
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
KR102042721B1 (ko) 2008-11-10 2019-11-11 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
CN102281870B (zh) 2008-12-10 2015-03-04 安徽中人科技有限责任公司 新型控释组合物
WO2010090677A1 (en) * 2008-12-10 2010-08-12 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP2358760B1 (en) 2008-12-19 2015-02-18 Momenta Pharmaceuticals, Inc. Characterization of o-linked glycans
SG172812A1 (en) 2008-12-31 2011-08-29 Revance Therapeutics Inc Injectable botulinum toxin formulations
EP2391419B1 (en) 2009-01-29 2019-06-12 ForSight Vision4, Inc. Posterior segment drug delivery
US9744237B2 (en) 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
AU2010214834B2 (en) 2009-02-19 2016-04-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
EP2406371B1 (en) 2009-03-13 2018-05-09 Allergan, Inc. Cells useful for immuno-based botulinum toxin serotype a activity assays
PT3281953T (pt) 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
PT2413947T (pt) 2009-04-01 2020-05-28 Revance Therapeutics Inc Métodos e composições para tratar condições de pele associadas à hiper-reatividade vascular
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20180027833A1 (en) 2009-04-24 2018-02-01 Nestec S.A. Shelf-stable fermented dairy products and methods of making same
CN105145818A (zh) 2009-04-24 2015-12-16 雀巢产品技术援助有限公司 货架稳定的发酵乳制品以及制备方法
US9539233B2 (en) 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
WO2013170052A1 (en) 2012-05-09 2013-11-14 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2445481B1 (en) 2009-06-18 2017-03-22 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
WO2011005577A1 (en) 2009-06-24 2011-01-13 Soparkar Charles N S Zinc supplementation to increase responsiveness to metalloprotease therapy
KR102328155B1 (ko) 2009-06-25 2021-11-17 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
KR101736775B1 (ko) 2009-06-30 2017-05-18 (주)아모레퍼시픽 복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
MX2012001071A (es) 2009-07-24 2012-10-09 Univ California Metodos y composiciones para mejorar el transporte de azucar, fermentacion de azucar mezclada, y produccion de biocombustibles.
IN2012DN00781A (ko) 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
BR112012005763B1 (pt) 2009-09-14 2020-06-09 Changhae Ethanol Co Ltd método de preparação para materiais bio-combustíveis
CA2783432A1 (en) 2009-12-15 2011-06-23 Stratley Ag Method for recovery of organic components from dilute aqueous solutions
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
DE212011100034U1 (de) 2010-01-20 2012-07-04 Theracoat Ltd. Material zur Behandlung von inneren Hohlräumen
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
WO2011103465A2 (en) 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
EA023397B1 (ru) 2010-05-26 2016-05-31 Селекта Байосайенсиз, Инк. Комбинированные вакцины с синтетическими наноносителями
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
MX342920B (es) 2010-07-30 2016-10-19 Medimmune Llc Metodo para purificar polipeptidos o inmunoconjugados activos.
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
EP2633074A1 (en) 2010-10-27 2013-09-04 Quantibact A/s Capture of target dna and rna by probes comprising intercalator molecules
US9284566B2 (en) 2010-11-03 2016-03-15 The Regents Of The University Of California Biofuel and chemical production by recombinant microorganisms via fermentation of proteinaceous biomass
FR2967913A1 (fr) 2010-11-29 2012-06-01 Vetalis Composition galenique adaptee a l'administration a un animal non-humain, utilisations de celle-ci et methodes associees
EP3248614A1 (en) 2011-01-07 2017-11-29 ReVance Therapeutics, Inc. Kits for topical application, removal, and inactivation of therapeutic or cosmetic botulinum toxin compositions
AU2012209274A1 (en) 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
WO2012112696A1 (en) 2011-02-15 2012-08-23 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
CA2827956C (en) 2011-02-23 2019-05-07 Ams Research Corporation Drug releasing pelvic treatment system and method
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
CN105853348B (zh) 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
ES2810098T3 (es) * 2011-03-31 2021-03-08 Medy Tox Inc Preparación liofilizada de toxina botulínica
BR112013025047A2 (pt) 2011-03-31 2017-02-14 Nestec Sa composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
GB2524906B8 (en) 2011-04-07 2016-12-07 Virdia Ltd Lignocellulose conversion processes and products
WO2012140118A1 (en) 2011-04-12 2012-10-18 Nestec S.A. Nutritional compositions including branched chain fatty acids for wound healing
JP2014512371A (ja) 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−ＨＩＣＡ及びシトルリンを含有する栄養組成物
EP3610889A1 (en) 2011-05-08 2020-02-19 LegoChem Biosciences, Inc. Protein-active agent conjugates and method for preparing the same
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
AU2012255132B2 (en) 2011-05-17 2017-05-25 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
MX340172B (es) 2011-06-17 2016-06-28 Halozyme Inc Formulaciones estables de una enzima degradadora de hialuronano.
US8586020B2 (en) 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US20130053792A1 (en) 2011-08-24 2013-02-28 Ablative Solutions, Inc. Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
KR20130022923A (ko) 2011-08-26 2013-03-07 삼성전자주식회사 가상 시점 합성 예측을 이용한 부호화/복호화 장치 및 부호화/복호화 방법
US9474689B2 (en) 2011-10-25 2016-10-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN107522664B (zh) 2011-10-27 2021-03-16 麻省理工学院 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN103930595A (zh) 2011-11-11 2014-07-16 Sio2医药产品公司 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备
WO2013087916A1 (en) 2011-12-15 2013-06-20 Nestec S.A. Extensional viscosity to promote safe swallowing of food boluses
US10582722B2 (en) 2011-12-15 2020-03-10 Societe Des Produits Nestle S.A. Cohesive thin liquids to promote safe swallowing in dysphagic patients
ES2749620T3 (es) 2011-12-30 2020-03-23 Halozyme Inc Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
MY175391A (en) 2012-04-26 2020-06-23 Adisseo France Sas Method of production of 2,4-dihydroxybutyric acid
US20150335576A1 (en) 2012-06-29 2015-11-26 Cytosorbents Corporation Methods of using polymers
CN106170582A (zh) 2012-07-03 2016-11-30 Sio2医药产品公司 药物包装的SiOx 阻隔物和涂布方法
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
ES2609654T3 (es) 2012-07-31 2017-04-21 Nestec S.A. Composición nutritiva para promover la salud del aparato locomotor de pacientes que sufren la enfermedad del intestino inflamatorio (IBD)
EP2880168B1 (en) 2012-08-05 2017-01-11 Absci, LLC Inducible coexpression system
WO2015020982A2 (en) 2013-08-04 2015-02-12 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
US10980865B2 (en) 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
US10894062B2 (en) 2012-08-10 2021-01-19 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
FR2996855B1 (fr) 2012-10-16 2016-11-11 Lesaffre & Cie Souches de levures pour la production de biomasse sur un substrat comprenant un sucre en c5, leurs procedes d'obtention et utilisations de la biomasse produite
WO2014066916A2 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
AU2013350328A1 (en) 2012-11-26 2015-07-09 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
EP2939025B1 (en) 2012-12-28 2018-04-25 Cellestis Limited A cell mediated immune response assay
BR122021009029B1 (pt) 2013-01-11 2022-02-01 Impossible Foods Inc Método de fabricação de réplica de queijo não láctea compreendendo um coacervado e produto obtido a partir do mesmo
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
US9650608B2 (en) 2013-02-22 2017-05-16 Medivet America, Llc Activating adipose-derived stem cells for transplantation
WO2014134577A1 (en) 2013-03-01 2014-09-04 Sio2 Medical Products, Inc. Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus
WO2014164928A1 (en) 2013-03-11 2014-10-09 Sio2 Medical Products, Inc. Coated packaging
US9937099B2 (en) 2013-03-11 2018-04-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging with low oxygen transmission rate
US10081654B2 (en) 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
CN105518021A (zh) 2013-03-15 2016-04-20 节奏制药公司 药物组合物
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
WO2014149280A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
US20160073659A1 (en) 2013-03-15 2016-03-17 Nusirt Sciences, Inc. Compositions, methods, and kits for treatment of pets
BR112015024757A2 (pt) 2013-03-26 2017-07-18 Premier Nutrition Corp métodos para aprimorar síntese de proteína muscular seguindo treinamento simultâneo
EP2981249A4 (en) 2013-04-02 2016-11-23 Stc Unm MESOPOROUS ALAN NANOPARTICLES AS A UNIVERSAL PLATFORM FOR ADSORPTION, PRESENTATION, AND ADMINISTRATION OF ANTIGENS
AU2013387115A1 (en) 2013-04-16 2015-11-05 Nestec S.A. Shelf-stable fermented dairy products and methods of making same
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN103257233B (zh) 2013-05-31 2015-08-05 南京祥中生物科技有限公司 一种同时可视化检测多种抗生素、非法添加剂及生物毒素的生物芯片及方法
BR112015032918B1 (pt) 2013-07-02 2021-09-28 Austrianova Singapore Pte Ltd Métodos para preparação de células encapsuladas para liofilização, composição e seus usos
MX2016001881A (es) 2013-08-15 2016-08-03 Lallemand Hungary Liquidity Man Llc Metodos para la mejora de rendimiento y produccion de producto en un microorganismo a traves del reciclaje de glicerol.
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
CN103705913A (zh) * 2013-12-27 2014-04-09 柳州市工人医院 A型肉毒毒素在制备治疗雷诺综合征药物的应用
WO2015103497A1 (en) 2014-01-02 2015-07-09 Trelys, Inc. Compositions and methods for biological production of amino acids in hydrogenotrophic microorganisms
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
MX2016009898A (es) 2014-01-29 2017-01-23 Vyome Biosciences Pvt Ltd Tratamientos para acne resistente.
JP6763777B2 (ja) 2014-02-06 2020-09-30 ゼリス ファーマシューティカルズ インコーポレイテッド 安定なペプチド製剤、および調製のための方法
BR112016018283A2 (pt) 2014-02-14 2017-08-08 Vesale Pharma Sa Composição que compreende bifidobacterium animalis ssp. lactis
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9389162B2 (en) 2014-04-10 2016-07-12 City University Of Hong Kong Detection of analyte using coffee-ring effect
CA2944784A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
WO2015160848A1 (en) 2014-04-15 2015-10-22 Industrial Microbes, Inc. Synthetic methanotrophic and methylotrophic microorganisms
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3137053B1 (en) * 2014-04-30 2020-06-17 Allergan, Inc. Formulations of biologics for intravesical instillation
WO2015184327A1 (en) 2014-05-30 2015-12-03 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016014750A1 (en) 2014-07-23 2016-01-28 Landy Toth Precision chemical ablation and treatment of tissues
ES2966909T3 (es) 2014-08-13 2024-04-25 Akeso Biomedical Inc Compuestos y composiciones antimicrobianos, y usos de los mismos
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
WO2016048689A1 (en) 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR102014028009B1 (pt) 2014-11-10 2023-04-18 Universidade Federal De Pelotas Composições filmogênicas para bioadesivos anestésicos tópicos (bats) para liberação controlada de princípios ativos e bioadesivos anestésicos tópicos
GB201421013D0 (en) 2014-11-26 2015-01-07 Turzi Antoine New standardizations & medical devices for the preparation of platelet rich plasma (PRP) or bone marrow centrate (BMC)
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
JP6821866B2 (ja) 2014-12-08 2021-01-27 ジェイワイエスケイ・スキン・ソリューションズ・プライベイト・リミテッドＪＹＳＫ Ｓｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｐｔｅ． Ｌｔｄ． 担体分子組成物および関連方法
EP3236944B1 (en) 2014-12-26 2020-07-15 Atterx Biotherapeutics, Inc. Methods and compositions for growth, storage, and use of bacterial preparations for wound and surface treatments
US11040022B2 (en) 2015-02-05 2021-06-22 William H. Cross, III Compositions and methods for pain relief
EP3268370A4 (en) 2015-03-11 2018-08-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CN107847533A (zh) 2015-03-13 2018-03-27 进化生物系统股份有限公司 代谢或隔绝游离的糖单体的组合物及其应用
WO2016154112A1 (en) 2015-03-20 2016-09-29 Children's National Medical Center Generating virus or other antigen-specific t cells from a naive t cell population
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
WO2016172658A2 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Microbiome regulators and related uses thereof
MX2017015149A (es) 2015-05-26 2018-03-28 Advaxis Inc Inmunoterapia personalizada basada en vectores de suministro y usos de esta.
US10555531B2 (en) 2015-08-11 2020-02-11 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CA2994304A1 (en) 2015-08-20 2017-02-23 Genomatica, Inc. Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
EP3359085A4 (en) 2015-10-12 2019-09-18 Toth, Landy CONTROLLED AND PRECISE TREATMENT OF HEARTWOVEN
CN113599533A (zh) 2015-11-25 2021-11-05 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
KR20180079452A (ko) 2015-11-25 2018-07-10 주식회사 레고켐 바이오사이언스 자기-희생기를 포함하는 접합체 및 이의 제조방법
WO2017089894A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
CN105363018B (zh) 2015-12-02 2019-08-30 南京碧迪可医药科技有限公司 一种硫肽环素的新用途
WO2017123367A1 (en) 2016-01-11 2017-07-20 Siemens Aktiengesellschaft Program randomization for cyber-attack resilient control in programmable logic controllers
MX2018008906A (es) 2016-01-21 2019-01-10 Selux Diagnostics Inc Metodos para pruebas rapidas de susceptibilidad antimicrobiana.
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
WO2017130059A1 (en) 2016-01-25 2017-08-03 Bio-Rad Innovations Digital microbiology
US11771752B2 (en) 2016-03-09 2023-10-03 Prime Bio, Inc. Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
CA3221966A1 (en) 2016-03-16 2017-09-21 Spogen Biotech Inc. Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes
BR112018068719A2 (pt) 2016-03-16 2019-01-22 Spogen Biotech Inc métodos para produzir uma resposta imunogênica em um animal aquático e composição farmacêutica
WO2017179775A1 (en) 2016-04-12 2017-10-19 Hugel Inc. Microstructure formulation techniques for botulinum toxin
SG11201808990QA (en) 2016-04-12 2018-11-29 Illustris Pharmaceuticals Inc Compositions for topical application of compounds
WO2017189614A1 (en) 2016-04-25 2017-11-02 uBiome, Inc. Method and system for characterizing skin related conditions
KR102423739B1 (ko) 2016-05-27 2022-07-21 입센 바이오팜 리미티드 트립토판 또는 타이로신으로 안정화된 액체 신경독 제형
US20170348263A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
US20190276859A1 (en) 2016-07-08 2019-09-12 Evonik Degussa Gmbh Method for the fermentative production of methionine or its hydroxy analog form by microorganisms comprising genes coding sugar phosphotransferase system (pts)
US10925837B2 (en) 2016-08-26 2021-02-23 Akina, Inc. Biodegradable polymer formulations for extended efficacy of botulinum toxin
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2018038585A1 (ko) 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
US11554108B2 (en) 2016-08-29 2023-01-17 Xeropedix, Inc. Methods and compositions for treating cutaneous fungal infections
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
AU2017351950A1 (en) 2016-10-26 2019-05-02 Oxy Solutions As Formulations
WO2018083692A1 (en) 2016-11-01 2018-05-11 Tamar Levin Novel methods for modulating protein expression in microorganisms
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US20180147357A1 (en) 2016-11-29 2018-05-31 Amir Marashi Delivery method for preparation and administration of pharmaceutical compositions
US11040090B2 (en) 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
WO2018112138A1 (en) 2016-12-15 2018-06-21 Anavi Goffer Sharon Treatment of mental, movement and behavioral disorders
WO2018112419A1 (en) 2016-12-15 2018-06-21 uBiome, Inc. Method and system for characterizing diet-related conditions
US20190343139A1 (en) 2016-12-27 2019-11-14 IMB Inc. Processing human milk for generating compositions of fortified human milk products
CN108322936B (zh) 2017-01-16 2023-06-02 中兴通讯股份有限公司 数据重传的方法及装置
WO2018136425A1 (en) 2017-01-17 2018-07-26 White Dog Labs, Inc. Proteinic biomass preparation comprising a non-native organism of the clostridia class
US20200121739A1 (en) 2017-01-18 2020-04-23 Evelo Biosciences, Inc. Bacteria for treating cancer
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
KR101776659B1 (ko) 2017-02-27 2017-09-11 주식회사 쿼드메디슨 마이크로 니들 및 이의 제조방법
US11642319B2 (en) 2017-03-24 2023-05-09 The Regents Of The University Of Colorado Targeted nanogels for urinary bladder therapies
WO2018195097A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of California Engineered commensal bacteria and methods of use
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2018206772A1 (de) 2017-05-11 2018-11-15 Immundiagnostik Ag Verfahren und testbesteck zur quantitativen bestimmung von biomarkern in fäkalproben
CN110913868A (zh) 2017-05-24 2020-03-24 Atgc 股份有限公司 用于治疗足痛疾病的包括肉毒杆菌毒素和透明质酸的药物组合物以及使用其治疗足痛疾病的方法
JP7096845B2 (ja) 2017-05-31 2022-07-06 アラーガン、インコーポレイテッド メラノサイトの活動亢進および／または過剰メラニンに関連する障害の治療のためのボツリヌス神経毒素
FR3067928B1 (fr) 2017-06-23 2020-02-28 Fondation Mediterranee Infection Procede de conservation d'un echantillon de bacteries
AU2018290765A1 (en) 2017-06-26 2020-01-23 Bonti, Inc. Clostridial neurotoxin formulations and use
EP3648780A1 (en) 2017-07-05 2020-05-13 Evelo Biosciences, Inc. Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
JP7208223B2 (ja) 2017-08-14 2023-01-18 プソマーゲン， インコーポレイテッド 疾患関連マイクロバイオーム特徴解析プロセス
US20210162026A1 (en) 2017-08-28 2021-06-03 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP3675883A4 (en) 2017-08-30 2021-05-12 Aobiome LLC MICROORGANISMS OXIDIZING AMMONIA FOR THE TREATMENT OF BUTTERFLY ERYTHEMA, ATHLETE'S FOOT, CONTACT DERMATITIS, SWEAT AND BODY ODORS
AU2018330323A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Extracellular vesicles from Prevotella
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
BR112020004264A2 (pt) 2017-09-08 2020-10-06 Evelo Biosciences, Inc. vesículas extracelulares bacterianas
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019075452A1 (en) 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
CA3082696A1 (en) 2017-11-13 2019-05-16 Extremochem, Lda. Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
CN111601610A (zh) 2017-11-14 2020-08-28 伊夫罗生物科学公司 使用布劳特氏菌属菌株治疗疾病的组合物和方法
US20210361560A1 (en) 2017-11-22 2021-11-25 Aobiome Llc Topical use and delivery of ammonia oxidizing microorganisms
US20210369599A1 (en) 2017-11-22 2021-12-02 Aobiome Llc Topical use and delivery of ammonia oxidizing microorganisms
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN108205008B (zh) 2017-12-28 2020-04-21 深圳大学 一种基于有机光电化学晶体管的毒素传感器及其制备方法
BR112020013872A2 (pt) 2018-01-07 2020-12-01 Avraham Amir microagulhas de alta carga e composições para aumento da pele
AU2019212338A1 (en) 2018-01-24 2020-08-13 Omnigen Research, Llc Bacillus combination for administration to animals
US20210052669A1 (en) 2018-01-31 2021-02-25 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using lachnospiraceae bacteria
JP2021515088A (ja) 2018-02-06 2021-06-17 レゲン ラブ エスエー 架橋ヒアルロン酸及びｐｒｐ／ｂｍｃとの組み合わせ
BR112020015639A2 (pt) 2018-02-06 2021-03-30 Evelo Biosciences, Inc. Composições e métodos para o tratamento de câncer e distúrbios imunológicos usando bactérias veillonella
KR102063475B1 (ko) 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
EP3758513A1 (en) 2018-02-28 2021-01-06 c-LEcta GmbH Enzymatic in-situ fortification of food with functional carbohydrates
WO2019178055A1 (en) 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Extracellular vesicles from burkholderia
WO2019178359A1 (en) 2018-03-15 2019-09-19 Adepthera Llc Gel-forming polypeptides
US20210015844A1 (en) 2018-03-14 2021-01-21 Beacon Medcare (Hk) Limited Composition for purification of biofluids
WO2019178490A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
WO2019178494A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
WO2019178487A2 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
US20190321427A1 (en) 2018-04-18 2019-10-24 G&S Laboratories, Inc. Compositions to Treat Anal Fissures
EP4295902A2 (en) 2018-05-03 2023-12-27 Crigasseni AG Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of clostridium difficile infection
WO2019226599A1 (en) 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
US11464858B2 (en) 2018-06-23 2022-10-11 University Of Wyoming Magnetic nanoparticle delivery system for pain therapy
CN112888454A (zh) 2018-09-13 2021-06-01 阿勒根公司 梭菌毒素-透明质酸组合物

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033625B2 (en) * 2005-10-06 2021-06-15 Allergan, Inc. Method for stabilizing a toxin
US11147878B2 (en) 2005-10-06 2021-10-19 Allergan, Inc. Animal protein-free pharmaceutical compositions
US11285216B2 (en) 2005-10-06 2022-03-29 Allergan, Inc. Animal protein-free pharmaceutical compositions
US11446382B2 (en) 2005-10-06 2022-09-20 Allergan, Inc. Animal protein-free pharmaceutical compositions
US11524075B2 (en) 2005-10-06 2022-12-13 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10973890B2 (en) 2016-09-13 2021-04-13 Allergan, Inc. Non-protein clostridial toxin compositions

Also Published As

Publication number Publication date
PT3432916T (pt) 2019-11-20
SI3436054T1 (sl) 2020-01-31
JP2019526611A (ja) 2019-09-19
CN109803672A (zh) 2019-05-24
PL3436054T5 (pl) 2023-01-30
US10973890B2 (en) 2021-04-13
RU2019110912A (ru) 2020-10-15
SI3436054T2 (sl) 2022-09-30
EP3436054A2 (en) 2019-02-06
KR20240023684A (ko) 2024-02-22
CY1122276T1 (el) 2020-11-25
US20230355724A1 (en) 2023-11-09
KR102635959B1 (ko) 2024-02-14
MX2019002835A (es) 2019-09-04
WO2018053021A1 (en) 2018-03-22
ES2755816T3 (es) 2020-04-23
TWI773686B (zh) 2022-08-11
CO2019003630A2 (es) 2019-06-28
EP3436054B2 (en) 2022-07-27
US10369190B2 (en) 2019-08-06
AU2017327369A1 (en) 2019-05-02
KR102444230B1 (ko) 2022-09-19
AU2017326253B2 (en) 2021-10-21
CL2019000586A1 (es) 2019-07-26
RU2762607C2 (ru) 2021-12-21
CY1122263T1 (el) 2020-11-25
HRP20191966T4 (hr) 2022-09-16
MX2023004911A (es) 2023-05-16
IL265109B1 (en) 2024-01-01
WO2018053004A2 (en) 2018-03-22
EP3639848A2 (en) 2020-04-22
CN117959415A (zh) 2024-05-03
KR20230004945A (ko) 2023-01-06
JP7217700B2 (ja) 2023-02-03
EP3436054B1 (en) 2019-08-14
ES2755816T5 (es) 2022-10-24
TW202247855A (zh) 2022-12-16
ES2755815T3 (es) 2020-04-23
PT3436054T (pt) 2019-11-19
RU2019110875A (ru) 2020-10-15
CA3035473A1 (en) 2018-03-22
AU2021282546A1 (en) 2022-01-06
RU2019110912A3 (ko) 2020-11-30
BR112019004935A2 (pt) 2019-06-04
DK3436054T3 (da) 2019-11-11
KR20220132013A (ko) 2022-09-29
CA3036095A1 (en) 2018-03-22
EP3639848A3 (en) 2020-12-16
RS59600B1 (sr) 2020-01-31
BR112019004929A2 (pt) 2019-06-04
PL3432916T3 (pl) 2020-04-30
EP3432916A1 (en) 2019-01-30
JP2022179500A (ja) 2022-12-02
IL308091A (en) 2023-12-01
HUE046449T2 (hu) 2020-03-30
US20190351034A1 (en) 2019-11-21
CN109803673A (zh) 2019-05-24
KR20190053214A (ko) 2019-05-17
SI3432916T1 (sl) 2020-01-31
EP3432916B1 (en) 2019-08-14
JP2019526609A (ja) 2019-09-19
US20230173041A1 (en) 2023-06-08
RS59600B2 (sr) 2022-10-31
HUE046290T2 (hu) 2020-02-28
IL265109B2 (en) 2024-05-01
DK3436054T4 (da) 2022-08-29
DK3432916T3 (da) 2019-11-11
US20230355723A1 (en) 2023-11-09
SA519401298B1 (ar) 2021-12-21
WO2018053004A3 (en) 2018-04-26
RU2019110875A3 (ko) 2021-01-12
LT3436054T (lt) 2019-11-25
PH12019500501A1 (en) 2019-05-27
TW201822786A (zh) 2018-07-01
US20210290739A1 (en) 2021-09-23
US20180071361A1 (en) 2018-03-15
PL3436054T3 (pl) 2020-06-15
HRP20191966T1 (hr) 2020-01-24
EP3626259A1 (en) 2020-03-25
KR102480965B1 (ko) 2022-12-26
KR20190053884A (ko) 2019-05-20
US20210369821A1 (en) 2021-12-02
IL265109A (ko) 2019-04-30
AU2017326253A1 (en) 2019-04-11
KR102558892B1 (ko) 2023-07-21

Similar Documents

Publication Publication Date Title
US10973890B2 (en) Non-protein clostridial toxin compositions
US20230158129A1 (en) Clostridial toxin - hyaluronic acid compositions
NZ792036A (en) Stabilized non-protein clostridial toxin compositions

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION